--- a
+++ b/clusters/3009knumclusters/clust_132.txt
@@ -0,0 +1,465 @@
+Histologically confirmed oligodendroglioma or mixed glioma
+Diagnosis: \r\n* Part A: Patients with recurrent or refractory solid tumors, including lymphoma and CNS tumors, are eligible; patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)\r\n* Part B: Patients with recurrent or refractory high grade glioma (World Health Organization [WHO] grade III/IV) including disseminated tumors (excluding diffuse intrinsic pontine glioma [DIPG]), not requiring surgical resection; patients must have had histologic verification of malignancy at original diagnosis or relapse\r\n* Part C: Patients with recurrent or refractory high grade glioma (WHO grade III/IV) and requiring surgical resection (excluding DIPG and disseminated tumors), who in the opinion of treating physicians, are medically stable to receive 3-4 doses of selinexor (8-10 days of treatment) before undergoing surgery without compromising the success of the procedure; note that if, in the opinion of treating physicians, current symptoms necessitate surgery before 3-4 doses will be able to be received, surgery should not be delayed to administer selinexor, and the patient would be ineligible for protocol therapy
+Histological evidence of World Health Organization (WHO) grade III anaplastic glioma or WHO grade II low grade glioma with locally diagnosed combined 1p/19q loss and the presence of an either IDH1 or IDH2, both as established by a local or referenced laboratory qualified for the study\r\n* Note: mixed gliomas are eligible, regardless of the degree of astrocytic or oligodendrocytic predominance, as long as the tumor is also co-deleted for 1p and 19q
+History of prior radiation therapy or chemotherapy for glioma; note: patients who have a history of prior low grade glioma (with or without a distant history of prior surgery for that glioma), but who have never received prior chemotherapy or radiation therapy for the glioma are eligible for the study
+Histologically proven diagnosis of glioblastoma (World Health Organization [WHO] grade IV) confirmed by central review prior to step 2 registration
+Patients must have high-grade bladder cancer as defined by 2004 World Health Organization (WHO)/International Society of Urological Pathology (ISUP) classification
+Patients with low grade glioma patients (World Health Organization [WHO] grades I and II) are not eligible
+Neuroendocrine tumors (NETs), grade 2 and grade 3 according to World Health Organization classification.
+Patients with a histologically confirmed diagnosis of high-grade glioma (HGG), medulloblastoma, CNS embryonal tumor (not otherwise specified [NOS]), ependymoma, or atypical teratoid rhabdoid tumor (ATRT) that is recurrent, progressive or refractory
+Patients with recurrent diffuse intrinsic pontine glioma (DIPG) with typical radiographic appearance who have undergone biopsy are eligible provided there is histologic confirmation of malignant glioma World Health Organization (WHO) II-IV; Rb1 screening for these patients is required only if adequate tissue is available
+Diagnosis of one of the following histologic subtypes of PTCL, pathologically-confirmed, as defined by the World Health Organization:
+Morphologically confirmed diagnosis of MDS or MDS/MPN in accordance with World Health Organization (WHO) diagnostic criteria
+Subject has morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) which is relapsed or refractory after failing at least 1 regimen and is not a candidate for established salvage treatment regimens
+Documented pathological evidence of MDS as defined by the World Health Organization (WHO) criteria
+Patients must have histologically or cytologically confirmed glioblastoma or other grade IV malignant glioma (i.e. gliosarcoma, small cell glioblastoma, etc.), recurrent after prior external beam fractionated radiotherapy and temozolomide chemotherapy
+Have histologically confirmed World Health Organization (WHO) grade II or III meningioma that is progressive or recurrent; metastatic meningiomas are allowed; participants must have failed maximal safe resection and radiation therapy
+Diagnosis of DIPG or high-grade glioma originating from the brain stem
+Subjects with any of the following tumors who have experienced relapse following front-line therapy, or who are refractory to front-line therapy, and subjects with tumors that carry a poor prognosis and have no known standard curative therapy are eligible;\r\n* Brain tumors of all World Health Organization (WHO) grades except diffuse intrinsic pontine glioma (DIPG); patients with DIPG are not eligible\r\n* Extracranial solid tumors including histiocytoses (e.g. Langerhans cell histiocytosis [LCH], juvenile xanthogranuloma [JXG], histiocytic sarcoma)
+World Health Organization (WHO) performance status =< 2
+Participants must have histologically confirmed glioblastoma or variants; subjects with initial diagnosis of a lower grade glioma are eligible if a subsequent biopsy is determined to be glioblastoma or variants
+Diagnosis of PTCL according to the most recent edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic or Lymphoid Tissues, as follows:
+Refractory or relapsed lymphoma (per World Health Organization (WHO) Classification system)
+Ependymoma (World Health Organization [WHO] grade II) or anaplastic ependymoma (WHO grade III) that has relapsed or become refractory to standard therapy; patients must have had histologic verification of their malignancy at original diagnosis or time of recurrence
+Diagnosis of de novo or secondary myelodysplastic syndrome (MDS), including chronic myelomonocytic leukemia, as defined by the 2008 World Health Organization classification system
+Patients must have histologically confirmed diagnosis of glioblastoma multiforme (GBM) or anaplastic glioma, World Health Organization (WHO) grade 3 or 4
+Patients with biopsy proven low grade glioma or astrocytoma, ependymoma, craniopharyngioma, meningioma, neurocytoma, medulloblastoma or gangliogliomas or other rare tumor requiring tumor bed or tumor irradiation; patients with a presumed diagnosis of optic glioma or gliomas based on imaging and clinical characteristics will also be allowed on this trial as it may be against the standard of care to biopsy some of these individuals (for example, a patient with neurofibromatosis [NF]-1 and an optic glioma will not require a biopsy for diagnosis)
+Patients with biopsy proven high-grade glioma (excluding glioblastoma multiforme [GBM]) and a gross total resection and patients with non-disseminated atypical teratoid rhabdoid (ATRT) patients may also be included
+An optic pathway glioma
+All patients must have radiographically progressive low-grade glioma (including NF1 related visual pathway gliomas) after failure of a carboplatin-containing regimen; patients do not require a biopsy to confirm the diagnosis
+Subject has documented, histologically locally confirmed, previously untreated CD20+ DLBCL (NOS) per World Health Organization (WHO) classifications (Swerdlow, 2008).
+At the time of surgery, frozen biopsy confirmation of high grade or malignant glioma by neuropathologist; biopsy confirmation of glioma or infiltrative glioma at time of surgery will be acceptable, provided that subject has prior pathology confirmation of high-grade glioma; if subject had previous diagnosis of low grade glioma, then the biopsy must show high grade glioma\r\n* To be confirmed at time of surgery, after registration in OnCore
+Participants must have prior diagnosis of glioma (astrocytoma, malignant astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, mixed oligo-astrocytoma), exclusive of ependymoma, ganglioglioma, pylocytic/pylomyxoid astrocytoma as confirmed by a neuropathologist or by a previous local pathology report
+A pathologically confirmed diagnosis of AML by World Health Organization (WHO) classification that is progressing.
+Patients with newly diagnosed DIPGs, defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible without histologic confirmation\r\n* Patients with brainstem tumors that do not meet these criteria or are not considered to be typical intrinsic pontine gliomas will only be eligible if the tumors are biopsied and proven to be an anaplastic astrocytoma, glioblastoma, gliosarcoma, diffuse midline glioma with histone H3 K27M mutation, or anaplastic mixed glioma; patients with pilocytic astrocytoma, fibrillary astrocytoma, gangliogliomas, or other mixed gliomas without anaplasia are not eligible\r\n* Patients with disseminated disease are not eligible, and magnetic resonance imaging (MRI) of spine must be performed if disseminated disease is suspected by the treating physician\r\n* Enrollment must be no later than 28 days after the date of radiographic diagnosis or surgery, whichever is the later date
+Patients must have refractory, progressive or recurrent confirmed low-grade glioma (World Health Organization [WHO] grade I or II) that was confirmed histologically at initial diagnosis
+Patients who are newly OR previously diagnosed with low grade glioma (LGG), who have not been treated with any modality besides surgery or corticosteroids; untreated astrocytomas or other eligible tumors (with the exception of subependymal giant cell astrocytoma) interpreted as low grade (World Health Organization [WHO] grade I and II), will be eligible for the study as below (4th edition WHO classification of central nervous system [CNS] tumors); if it is clinically suspected that the previously untreated progressive low grade astrocytoma has evolved to a higher grade tumor, it is recommended a biopsy be performed; patients with metastatic disease are allowed on study
+Glial tumors (including patients with leptomeningeal disease)\r\n* Astrocytic tumors \r\n** Low-grade astrocytoma (variants: fibrillary, protoplasmic gemistocytic, mixed, not otherwise specified [NOS])\r\n** Pilocytic astrocytoma\r\n** Pleomorphic xanthoastrocytomas \r\n** Infantile desmoplastic astrocytoma \r\n** Pilomyxoid astrocytoma\r\n* Low-grade oligodendroglioma\r\n* Low-grade oligoastrocytoma
+Low grade glioma NOS
+World Health Organization (WHO) performance status equal to 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.
+Chronic myelomonocytic leukemia (CMML) should be classified as:\r\n* CMML-1 or CMML-2 based on World Health Organization (WHO) classification of 2008
+Patients must have a newly diagnosed or recurrent World Health Organization (WHO) grade II astrocytoma, oligoastrocytoma or oligodendroglioma that has been histologically confirmed by prior biopsy or surgical resection; if the pathological diagnosis was made outside of University of California San Francisco (UCSF), the pathology must be reviewed and confirmed at UCSF
+Histologically proven diagnosis of high-grade glioma, including anaplastic glioma (WHO grade III with 1p/19q chromosomes intact), glioblastoma (WHO grade IV) or gliosarcoma (WHO Grade IV);
+Patients must have a histologic diagnosis of meningioma, World Health Organization (WHO) grade 2 or 3 (atypical or anaplastic)
+recurrent glioblastoma
+Diagnosis of CMML as defined by the World Health Organization (WHO) criteria.
+Histologically confirmed atypical meningioma, World Health Organization (WHO) grade II, Simpson grade 4-5 that has been either subtotally resected or biopsied; OR
+RR DLBCL per the 2008 World Health Organization (WHO) classification of hematopoietic and lymphoid tumors (Swerdlow et al, 2008).
+Glioblastoma.
+Pathological criteria - patients must have a newly diagnosed or recurrent World Health Organization (WHO) grade II glioma (defined as an astrocytoma, oligodendroglioma, or oligoastrocytoma) that is to be histologically confirmed by clinically indicated resection; if patients have already undergone biopsy and have pathologic diagnosis of WHO grade II glioma, pathology must be reviewed and confirmed at University of California San Francisco (UCSF)
+Stratum A, currently closed to enrollment: Patients must have a recurrent, progressive or refractory DIPG following radiation therapy with or without chemotherapy\r\n* Histologic diagnosis is not required for patients with typical imaging findings of DIPG (defined as patients with a diffuse expansile mass centered in and involving at least 2/3 of the pons); patients with brainstem tumors who have undergone biopsy with a diagnosis of high-grade glioma or diffuse infiltrating glioma are also eligible
+Stratum B: Patients must have a histologically confirmed diagnosis of a non-brainstem high-grade glioma (NB-HGG) that is recurrent, progressive or refractory following therapy which included radiotherapy; spinal primary disease is eligible
+EXCLUSION CRITERIA FOR STRATUM C: Patients with diffuse intrinsic pontine or other brainstem high-grade glioma and those with primary spinal cord tumors
+Inclusion Criteria:\n\n        Adult participants (greater than or equal to 18 years old):\n\n          -  Histologically confirmed de novo (primary) Glioblastoma Multiforme with unequivocal\n             tumor progression or recurrence.\n\n          -  In case of testing at the time of first progression: either at least 3 months after\n             the end of radiotherapy or have tumor progression that is clearly outside the\n             radiation field or have tumor progression unequivocally proven by surgery/biopsy\n\n          -  Absence of any psychological, familial, sociological or geographical factors\n             potentially hampering compliance with the study protocol and follow-up schedule; such\n             conditions should be assessed with the patient before registration in the trial.\n\n          -  Availability of adequate biological material (formalin-fixed paraffin embedded [FFPE]\n             tumor) for central testing of Epithelial Growth Factor Receptor (EGFR) amplification\n\n          -  Presence of EGFR amplification confirmed by central assessment; participants with\n             undetermined EGFR status are excluded\n\n          -  World Health Organization (WHO) Performance status 0 - 2\n\n          -  No more than one line of chemotherapy (concurrent and adjuvant Temozolomide based\n             chemotherapy including in combination with another investigational agent is considered\n             one line of chemotherapy). Chemotherapy must have been completed at least 4 weeks\n             prior to randomization.\n\n          -  Post surgery MRI within 48 hours following surgery, however an MRI scan has to be done\n             within 2 weeks prior to randomization.\n\n          -  Surgery completed at least 2 weeks before randomization and patients should have fully\n             recovered as assessed by investigators.\n\n        Pediatric sub-study participants (less than 18 years old):\n\n          -  The study will only include patients under 3 years of age when results of a juvenile\n             repeated mouse toxicity study become available and are favorable to support use in\n             patients aged under 3 years.\n\n          -  Histologically proven high grade glioma (HGG: WHO grade III glioma [e.g anaplastic\n             astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma], grade IV\n             glioma [e.g glioblastoma, gliosarcoma] or diffuse intrinsic pontine glioma [DIPG]).\n\n          -  Must either have recurrent/progressive tumor or, if newly diagnosed, have completed\n             any planned radiation therapy at least 4 weeks prior to first dose of ABT-414.\n\n          -  The tumor tissue must have been determined to have EGFR amplification, (by local or\n             other testing service).\n\n          -  Availability of adequate biological material for retrospective confirmatory central\n             testing of EGFR amplification\n\n          -  Participant has sufficiently recovered from previous therapy. The investigator\n             believes that benefit of treating the pediatric subject with ABT-414 outweighs the\n             expected risks and that this treatment is in the best interests of the pediatric\n             subject.\n\n        Exclusion Criteria:\n\n        Adult population (greater than or equal to 18 years old):\n\n          -  Prior treatment with nitrosoureas\n\n          -  Prior treatment with bevacizumab\n\n          -  Previous exposure to Epithelial Growth Factor Receptor (EGFR) targeted agents,\n             including EGFRvIII targeting agents\n\n          -  Prior discontinuation of temozolomide chemotherapy for toxicity reasons\n\n          -  Prior Radiation Therapy (RT) with a dose over 65 Gy, stereotactic radiosurgery or\n             brachytherapy unless the recurrence is histologically proven\n\n          -  Previous other malignancies, except for any previous malignancy which was treated with\n             curative intent more than 5 years prior to randomization, and except for adequately\n             controlled limited basal cell carcinoma of the skin, squamous carcinoma of the skin or\n             carcinoma in situ of the cervix\n\n          -  Women of childbearing potential must have a negative serum or urine pregnancy test\n             (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to\n             randomization.\n\n          -  No history of wheat allergies and Coeliac disease.\n\n          -  No EIAED, patients who require anti-convulsant therapy must be taking non-enzyme\n             inducing antiepileptic drugs (non-EIAED). Patients previously on EIAED must be fully\n             switched to non-EIAED at least 2 weeks prior to randomization.\n\n        Pediatric sub-study (less than 18 years old):\n\n          -  (For recurrent disease) No prior RT with a dose over 65Gy to the brain, stereotactic\n             radiosurgery or brachytherapy unless the recurrence is histologically proven\n\n          -  No current or recent (within 4 weeks or 5 half-lives (whichever is shorter) before\n             enrollment) treatment with another investigational drug\n\n          -  Female participants of childbearing potential must have a negative serum or urine\n             pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72\n             hours prior to randomization.
+Diagnosis of a b-cell malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).
+Phase I: histologically confirmed grade III or IV malignant glioma\r\nPhase II: histologically confirmed grade IV malignant glioma (GBM)\r\n* Note: GBM variants and secondary GBM, and suspected secondary GBM are allowed for both phase I and phase II
+There must be an interval of at least 12 weeks from the completion of standard front line therapy to study registration unless there is unequivocal evidence for tumor recurrence per RANO criteria; when the interval is less than 12 weeks, the use of perfusion imaging and/or positron emission tomography (PET) scan is allowed to differentiate between unequivocal evidence of tumor recurrence and pseudo-progression; standard front line therapy is as described below:\r\n* For grade IV malignant gliomas (GBM): standard front line therapy for newly diagnosed GBM must include maximal feasible surgical resection (biopsy alone allowed), radiotherapy, and temozolomide chemotherapy; if the tumor was initially diagnosed as either a grade II or III tumor and now has recurred or progressed as a grade IV GBM, it will be considered a secondary recurrent grade IV GBM and will be eligible for this study as long as prior treatment included maximal feasible surgical resection (biopsy alone allowed), radiotherapy, and temozolomide chemotherapy\r\n* For grade III malignant gliomas with 1p 19q codeletions: standard front line therapy for newly diagnosed grade III malignant gliomas must include maximal feasible surgical resection (biopsy alone allowed), radiotherapy, and chemotherapy (procarbazine, lomustine, and vincristine sulfate [PCV] or temozolomide); if the patient did not receive any or all components of the standard front line therapy as detailed above for newly diagnosed grade III gliomas with 1p 19q codeletions and the tumor then recurred or progressed, s/he must first receive at least one prior standard therapy or any appropriate combination of the components of standard therapy as detailed above and must experience further recurrence or progression before s/he is deemed eligible for this study; if the tumor was initially diagnosed as a grade II glioma with 1p 19q codeletions and now has recurred or progressed as a grade III tumor, it will be considered a secondary recurrent grade III glioma with 1p 19q codeletions and will be eligible for this study as long as prior treatment included maximal feasible surgical resection (biopsy alone allowed), radiotherapy, and chemotherapy (PCV or temozolomide)\r\n* For grade III malignant glioma without 1p 19q codeletions: standard front line therapy for newly diagnosed grade III malignant gliomas must include maximal feasible surgical resection (biopsy alone allowed), radiotherapy, and temozolomide chemotherapy; if the tumor was initially diagnosed as a grade II glioma without 1p 19q codeletions and now has recurred or progressed as a grade III tumor, it will be considered a secondary recurrent grade III glioma without 1p 19q codeletions and will be eligible for this study as long as prior treatment included maximal feasible surgical resection (biopsy alone allowed), radiotherapy, and temozolomide chemotherapy
+Patients must have a clinical and histopathologic diagnosis of diffuse astrocytoma (World Health Organization, WHO, grade II, III or IV astrocytoma), have completed > 80% of prescribed concurrent radiation therapy and adjuvant temozolomide without Common Terminology Criteria for Adverse Events (CTCAE) grade 4 leukopenia, neutropenia, or thrombocytopenia, and be greater than 7 months from the time of completion of concurrent chemoradiotherapy, with stable disease by neuroimaging
+Histologically confirmed Rb1 positive primary recurrent, progressive, or refractory central nervous system tumors; patients with low grade gliomas are excluded
+Participants must have histologically confirmed glioblastoma and evidence of recurrence > 2 months since last cycle of temozolomide or other alkylating agent; patients with low-grade tumors who have progressed to glioblastoma are eligible
+Patients with histologically confirmed glioblastoma or other grade IV malignant glioma (i.e. gliosarcoma, small cell glioblastoma, etc.), recurrent after prior external-beam fractionated radiotherapy and temozolomide chemotherapy
+Patient must have a documented diagnosis of myelodysplastic syndrome (MDS) of at least three months duration (MDS duration >= 3 months) according to World Health Organization (WHO) criteria or non-proliferative chronic myelomonocytic leukemia (CMML) (white blood cells [WBC] =< 12,000/L)
+Subjects must have pathologically confirmed low grade glioma with histologic subtypes interpreted as World Health Organization (WHO) grade I and II including:\r\n* Juvenile pilocytic astrocytoma (JPA) \r\n* Pleomorphic JPA \r\n* Diffuse astrocytoma (fibrillary, gemistocytic, giant cell, or pleomorphic xanthoastrocytoma)\r\n* Subependymal giant cell astrocytoma (SEGA)\r\n* Low grade oligoastrocytoma\r\n* Low grade oligodendroglioma\r\n* Pilomyxoid astrocytoma\r\n* Low grade glioma not otherwise specified (NOS)
+ARM I: Patients must have histologically proven unmethylated MGMT supratentorial high-grade glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed astro oligodendroglioma or glioblastoma)
+ARM II: Patients must have histologically proven supratentorial methylated MGMT high-grade glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed astro oligodendroglioma or glioblastoma)
+Patients with pathology confirmed newly diagnosed World Health Organization (WHO) grade IV glioma
+Have a histologically proven well-differentiated neuroendocrine tumor (World Health Organization [WHO] grade 1, grade 2, or morphologically and/or clinically well-differentiated grade 3)
+Participants with a diagnosis of recurrent, progressive, or refractory low grade glioma (LGG)
+STRATUM B: Participants with low grade glioma (LGG) or diffuse intrinsic pontine glioma (DIPG)
+Histologically confirmed diagnosis of World Health Organization grade IV malignant glioma
+Participant has a prior histologically-confirmed diagnosis of a grade III or IV glioma, or has a prior histologically-confirmed diagnosis of a grade II glioma and now has radiographic progression consistent with a grade III or IV malignant glioma (MG)
+Patients must have histologically proven glioblastoma or gliosarcoma which is progressive or recurrent (per RANO criteria) following radiation therapy and temozolomide
+Must have a clinical diagnosis of Glioblastoma (GBM)
+Patient must have one of the following: \r\n* For stratum 5: non NF-1 associated low grade glioma (LGG) (other than pilocytic astrocytoma or optic pathway glioma) \r\n* For stratum 1 or 2: non NF-1, non-optic pathway pilocytic astrocytoma; note: all patients with non NF-1 associated optic pathway glioma with or without tissue must be enrolled on stratum 4
+NF-1 patients with radiographic evidence of a progressive, recurrent or refractory low grade glioma, with or without pre-treatment tumor tissue
+Patients will be assigned to one of 6 strata prior to enrollment; all BRAF assessments used for stratification below must be done at the Lindeman and Ligon Labs at Brigham and Women’s Hospital using the same procedures as described in this protocol; assessments for both BRAF V^600E mutation and BRAF KIAA1549 fusion are required for patients who will enroll on strata 1, 2 and 5 \r\n* Stratum 1: patients with non NF-1 associated progressive, recurrent or refractory pilocytic astrocytoma with pre-trial tumor material available and with a BRAF aberration i.e. BRAFV^600E mutation and/or BRAF KIAA1549 fusion as determined by IHC and FISH, respectively; patients with optic pathway glioma are excluded\r\n* Stratum 2: patients with non NF-1 associated progressive, recurrent or refractory pilocytic astrocytoma with pre-trial tumor material available and without a BRAF aberration i.e. BRAF^V600E mutation and/or BRAF KIAA1549 fusion as determined by IHC and FISH, respectively; patients with optic pathway glioma are excluded\r\n* Stratum 3: patients with neuro-fibromatosis 1 (NF-1) associated progressive, recurrent or refractory low grade glioma (World Health Organization [WHO] grade I & II), with or without tissue\r\n* Stratum 4*: patients with non-NF1 associated progressive, recurrent or refractory optic pathway glioma with or without tissue available for BRAF evaluation\r\n* Stratum 5: patients with non NF-1 associated progressive, recurrent or refractory low grade glioma other than pilocytic astrocytoma or optic pathway glioma with a documented BRAF aberration identified in pre-trial tumor material\r\n* Stratum 6: patients with non-NF-1 associated progressive, recurrent or refractory low grade glioma (other than optic pathway glioma [OPG]) with tissue available for BRAF analyses who cannot be classified into stratum 1, 2 or 5 due to inadequate tissue quality, assay failure, etc\r\n**Clarification: Stratum 4 was specifically designed for patients with hypothalamic/optic pathway gliomas; the intent is that if there is any optic chiasm invasion regardless of where the tumor is originating from (chiasm vs. hypothalamus vs. other location), the patient should be enrolled on Stratum 4, regardless of whether the tumor has been biopsied or not; obviously, there are some tumors that include part of the hypothalamus and clearly do NOT include the chiasm at all; in these situations, and if the tumor is a biopsy proven pilocytic astrocytoma, these patients should be enrolled on Stratum 1 or 2 (depending upon BRAF status)
+Histopathological evidence of glioblastoma or gliosarcoma, World Health Organization (WHO) grade IV
+STRATUM B: Histological confirmation (at diagnosis or relapse) of a recurrent or progressive grade II-IV glioma (including DIPG)
+A pathologically confirmed diagnosis of AML by World Health Organization (WHO) classification.
+Histopathologically proven previous diagnosis of medulloblastoma or grade III or IV glioma
+Radiology evidence of reMB or recurrent grade III and IV glioma; patients will be considered for a biopsy or resection of the recurrent/progressive tumor at the discretion of the treating neurosurgeon and neuro-oncologist
+Patients who need definitive radiotherapy for treatment of recurrent MB or recurrent grade III or IV glioma
+Must have pathologically documented, and definitively diagnosed World Health Organization (WHO) grade 4, glioblastoma
+Histologically confirmed diagnosis of high-grade glioma (any histology, including but not limited to glioblastoma, astrocytoma, and oligodendroglioma) in any tumor sample and presence of histone H3 K27M mutation by a Clinical Laboratory Improvement Act (CLIA)-approved immunohistochemistry or deoxyribonucleic acid (DNA) sequencing test on any glioma tumor sample
+Patients must have histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme), established by biopsy or resection not more than 3 months prior to registration
+First disease progression or disease recurrence (>= 1 cm and =< 5 cm) of a partially or completely resectable, supratentorial World Health Organization (WHO) grade IV malignant glioma (GBM or gliosarcoma) based on imaging studies with measurable disease
+Histopathologically proven diagnosis of glioblastoma or gliosarcoma prior to registration by pathology report
+Diagnosis of recurrent or progressive histologically confirmed World Health Organization (WHO) grade I-III meningioma which has failed maximal safe resection and radiation therapy
+Subject has a diagnosis of high-grade glioma, medulloblastoma, ependymoma or Diffuse intrinsic pontine glioma (DIPG) that is recurrent or progressive. Subjects with neurofibromatosis type 1 (NF-1) associated tumors are eligible if the meet all other eligibility criteria.
+Subject has any prior history of malignancies, other than high-grade glioma, medulloblastoma, ependymoma or DIPG (Note: radiation-associated gliomas are excluded from enrollment)
+Patients must have histologically confirmed low or high grade glioma (grade II-IV)
+Histologically confirmed or radiographic evidence of recurrent/progressive high-grade glioma after treatment with bevacizumab
+Diagnosis of AML by World Health Organization (WHO) criteria. Patients with high risk myelodysplastic syndrome (MDS) as defined by the presence of >= 10% blasts are also eligible at the discretion of the principal investigator
+Patients with a diagnosis BPDCN according to World Health Organization (WHO) classification confirmed by hematopathology;
+Histological confirmation of supratentorial glioblastoma (also known as astrocytoma grade IV, gliosarcoma) amenable to surgical resection =< 28 days prior to registration
+Histologically proven diagnosis of grade 1, 2, or 3A FL
+Any patient with a biopsy proven diagnosis of chondrosarcoma that is grade I, II or III or
+Histopathologically proven diagnosis of ependymoma, medulloblastoma, pineoblastoma/pineocytoma, choroid plexus carcinoma/papilloma, chordoma, gliomatosis cerebri, brainstem glioma, midline glioma, ATRT, atypical/malignant meningioma, gliosarcoma or primary brain sarcoma prior to registration as confirmed by National Cancer Institute (NCI) Laboratory of Pathology
+Patients must have histologically confirmed ND or R/R PTCL defined according to the 2016 World Health Organization (WHO) classification criteria, with no accepted curative options\r\n* Patients with extranodal natural killer (NK)/T-cell lymphoma may only be allocated to treatment Arm D
+Patients must have suspected recurrent malignant glioma (WHO grade III-IV), including recurrent glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and anaplastic ependymoma; stereotactic biopsies will be performed to confirm recurrent malignant glioma prior to initiating the treatment
+Patients must have a presumed newly identified high grade glioma based on clinical and radiologic evaluation; pathologic confirmation of high grade glioma must be made at the time of stereotactic biopsy or resection on frozen section by a neuropathologist prior to NSC-CRAd-S-pk7 injection; if this is not possible, the injection will not be performed and the subject will no longer be eligible for the study
+Patients must have a recurrent supratentorial WHO grade III malignant glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma, ependymoma) or WHO grade IV malignant glioma (glioblastoma, gliosarcoma) based on imaging studies with measurable disease (>= 1 cm and =< 5.5 cm of contrast-enhancing tumor); the prior histopathology must be consistent with a World Health Organization (WHO) grade III or IV malignant glioma confirmed by the study pathologist, Roger McLendon, or his designee; there is no standard of care treatment for children with grade III/IV gliomas; patients must have completed first-line treatments including surgical procedure and a minimum of 54Gy of radiation prior to participating in this trial
+Patients must have histologically-proven, recurrent supratentorial grade IV glioblastoma (or grade III IDH-wildtype anaplastic astrocytoma), for which a complete surgical resection is unsafe due to location, shape, or size of the tumor. Diagnosis of recurrence will be established by biopsy and frozen section immediately prior to initiating LITT procedure. If findings on frozen section are not consistent with recurrence (glioblastoma or recurrent IDH-wildtype anaplastic astrocytoma), decision to proceed with LITT procedure will be at the discretion of the neurosurgeon (only patients with histologically-proven recurrent tumor will be evaluable for efficacy).
+Have pathologically-proven GB, gliosarcoma (World Health Organization [WHO] IV), or anaplastic astrocytoma (WHO III) in recurrence after treatment with bevacizumab
+Patients must have histologically proven glioblastoma multiforme (GBM) or gliosarcoma (GS)
+Histologically confirmed diagnosis of malignant glioma by enrolling institution:\r\n* World Health Organization (WHO) grade IV tumors (glioblastoma [GBM] or its variants)\r\n* WHO grade III anaplastic astrocytoma or oligodendroglial tumors or\r\n* WHO grade II gliomas, if magnetic resonance imaging (MRI) shows contrast enhancement
+Evidence of an active optic glioma or other low-grade glioma, requiring treatment with chemotherapy or radiation therapy; patients not requiring treatment are eligible for this protocol
+Have histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma); participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made
+Be at first or second relapse; Note: relapse is defined as progression following initial therapy (i.e., radiation +/- chemotherapy); for participants who had prior therapy for a low-grade glioma, the surgical diagnosis of a high-grade glioma will be considered the first relapse
+Histologically confirmed PTCL as defined by World Health Organization (WHO) 2008 criteria
+Patients must have a recurrent supratentorial WHO grade IV malignant glioma based on imaging studies with measurable disease (>= 1 cm and =< 5.5 cm of contrast-enhancing tumor); prior histopathology consistent with a World Health Organization (WHO) grade IV malignant glioma confirmed by the study pathologist, Roger McLendon, or his designate
+Recurrent or multifocal high grade glioma (HGG)
+Diagnosis of MDS as defined by the World Health Organization (WHO) diagnostic criteria
+Patients must have pathologic diagnosis of anaplastic astrocytoma (defined as WHO grade III, or glioblastoma/gliosarcoma, WHO grade IV, which are confirmed by National Cancer Institute (NCI) laboratory of pathology; if the pathology diagnosis is anaplastic glioma or anaplastic oligoastrocytoma, evidence of either intact 1p/19q chromosomes or molecular features suggesting astrocytic tumor must be present; (including, but not limited to ATRX, p53)
+Patients with relapsed or refractory high grade glioma (HGG) defined was histologically confirmed World Health Organization (WHO) grade III or WHO grade IV glioma (i.e. glioblastoma multiforme or anaplastic astrocytoma); patients must have had histologic verification of malignancy at original diagnosis or relapse; metastatic disease to the spine is eligible; patients may be in first, second, or third relapse; subjects with intrinsic brain stem gliomas may be eligible if histologically confirmed; please contact study chair prior to enrollment
+Diagnosis of AML based on 2008 World Health Organization (WHO) criteria; AML may be de novo, following a prior hematologic disorder, including MDS or Philadelphia chromosome-negative myeloproliferative neoplasm, and/or therapy-related
+PHASE II: Patients must have histologically confirmed R/R NHL (as defined by World Health Organization [WHO] criteria); in addition, patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies; patients with DLBCL will be eligible if there is no available standard therapy
+Patients must have pathologically proven diagnosis of high grade glioma
+Newly diagnosed, histologically-confirmed supratentorial World Health Organization (WHO) grade IV gliomas including glioblastoma (all variants) and gliosarcoma
+Recurrent glioma, or tumor involving the brainstem or cerebellum; prior low-grade glioma without prior RT, now with malignant progression are eligible
+Patients with World Health Organization (WHO) class III or IV pulmonary hypertension
+Patients must have a prior diagnosis of grade IV glioma (glioblastoma) per 2016 World Health Organization (WHO) criteria, that has progressed after standard radiotherapy (RT) and temozolomide (TMZ) (Note: Pathology will need to be reviewed locally but registration can occur based on pathology report)
+Histologically documented diagnosis (based on the 2008 World Health Organization [WHO] Classification) of one of the following:
+Pathologically documented, and definitively diagnosed recurrent World Health Organization (WHO) Grade IV astrocytoma (GBM).
+Patients must have histologically confirmed initial diagnosis of primary intracranial World Health Organization (WHO) Grade IV malignant glioma (glioblastoma, GBM), now recurrent. Patients with recurrent disease whose initial diagnostic pathology confirmed glioblastoma will not need re-biopsy. Alternately, patients with prior intracranial low-grade glioma or anaplastic glioma will be eligible, if histologic assessment demonstrates transformation to GBM (first diagnosis of secondary GBM).
+Patients must have radiographic evidence of recurrent/progressive GBM after prior therapy (biopsy or resection and chemoradiation); 1st recurrence of GBM only, per Response Assessment in Neuro-Oncology Criteria (RANO) criteria. Histologically documented transformation from a lower grade gliomas will be considered first recurrence.
+Diagnosis of GBM (World Health Organization [WHO] grade IV); patients who are participating in the optional pre-operative pharmacokinetic study may have presumed GBM based on clinical/radiological findings; however, patient must have histologically confirmed GBM before continuing to receive DSF with concurrent RT/TMZ
+Previous histologic diagnosis of glioblastoma, transformation to glioblastoma or gliosarcoma established by biopsy or resection prior to enrollment as evident on National Institutes of Health (NIH) or outside pathology
+Patients with recurrent diffuse intrinsic pontine glioma (DIPG)
+Subjects must have histologically or cytologically confirmed World Health Organization (WHO) grade 4 glioma for which a clinically indicated tumor resection is planned
+Histopathologically proven newly-diagnosed, supratentorial glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV)
+Histologically confirmed GBM, WHO grade IV. GBM variants and secondary GBM are allowed in any recurrence (including multiple) and have been treated with radiation and chemotherapy.
+PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Have histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma); participants will also be eligible if the original histology was lower grade glioma and there is suspected transformation to glioblastoma based on imaging findings; if the final pathology report after resection fails to confirm recurrent glioblastoma or gliosarcoma, the subject will be followed for adverse events (AEs) and survival, but excluded for other primary and secondary objective analysis; the subject will be replaced
+PHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Have histologically confirmed World Health Organization grade IV glioma (glioblastoma or gliosarcoma)
+PHASE I: Have histologically confirmed World Health Organization WHO grade IV glioma (glioblastoma or gliosarcoma); participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made
+Subjects must have histologically confirmed diagnosis of World Health Organization (WHO) grade III or IV malignant glioma
+Subjects must be within 12 weeks of last major neurosurgical procedure for the high-grade glioma (craniotomy, open biopsy, or stereotactic biopsy)
+Histologically confirmed diagnosis of World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma)
+Recurrent medulloblastoma or recurrent high grade glioma
+Histopathologically confirmed glioblastoma or gliosarcoma (WHO Grade IV) confirmed by local pathology tissue screening.
+Radiologic evidence of first recurrence after initial treatment (including surgery, radiation, and temozolomide) or tumor refractory to initial treatment without subsequent treatment in glioblastoma or gliosarcoma (WHO Grade IV). Transformation from a lower grade glioma previously treated with radiation and/or temozolomide to glioblastoma will be considered first recurrence for the purpose of this trial
+Patients must have histologically or cytologically confirmed diagnosis of mycosis fungoides (MF), Sezary syndrome (SS) or primary cutaneous CD30-positive lymphoproliferative disorder, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL) (pc-ALCL) as defined by the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissue
+For Part 1 of the study, participants must have histopathologically confirmed diagnosis of R/R, DLBCL, FL, MZL/MALT, MCL, or other Sponsor approved NHL subtypes according to the World Health Organization (WHO) classification 2008 for which standard measures do not exist or are no longer effective.
+Patients must have histologically confirmed diagnosis of World Health Organization (WHO) grade 4 malignant glioma and radiographic evidence of recurrence or disease progression (as defined by the Response Assessment in Neuro-Oncology [RANO] criteria as a greater than 25% increase in the largest bi-dimensional product of enhancement or a new enhancing lesion, or a significant increase in T2-weighted-Fluid-Attenuated Inversion Recovery [T2/FLAIR] abnormality without another co-morbid cause)
+First or second recurrence of MG (WHO grade III or IV glioma or astrocytoma) in surgically accessible areas with prior histologic diagnosis of MG
+World Health Organization (WHO) performance status 0-2
+World Health Organization Performance Status of 0 to 1.
+Patients with low grade glioma are not eligible
+Patients must have a diagnosis of AML as per World Health Organization (WHO) Classification of Hematologic Neoplasms
+Eligibility Criteria\n\n          -  Age: 3-21 years.\n\n          -  Group 1 or Group 3: histologically proven initial diagnosis of primary malignant brain\n             tumor, with no known curative treatment options.\n\n          -  Group 2: histologically proven initial diagnosis of high-grade glioma (WHO grade III\n             and IV), ependymoma, medulloblastoma, or other primary central nervous system tumor.\n\n          -  Group 3b: Patients with a radiographic diagnosis or histologically proven diagnosis of\n             diffuse intrinsic pontine glioma (DIPG).\n\n          -  MRI confirmation of tumor progression or regrowth.\n\n          -  Patients must be able to swallow whole capsules.\n\n          -  Patients with metastatic disease are eligible for enrollment.\n\n          -  Lansky or Karnofsky performance status score must be > 50%.\n\n          -  Seizure disorders must be well controlled on antiepileptic medication.\n\n          -  DIPG patients enrolled to Group 3b must not have been previously treated with\n             radiation or any medical therapy.\n\n          -  Patients previously treated with temozolomide, cyclophosphamide, and/or etoposide are\n             eligible for enrollment.\n\n        Exclusion Criteria\n\n          -  Prior invasive malignancy, other than the primary central nervous system tumor, unless\n             the patient has been disease free and off therapy for that disease for a minimum of 3\n             years\n\n          -  Patients with baseline QTc interval of more than 470 msec at study entry, and patients\n             with congenital long QTc syndrome.\n\n          -  Active autoimmune disease
+Histologically confirmed diagnosis of supratentorial WHO grade III or IV glioma (high grade glioma) that has undergone surgical biopsy or resection followed by adjuvant chemoradiotherapy, that has evidence of recurrence or progression based on imaging studies and surgical resection of the enhancing tumor is clinically indicated
+History of AML according to World Health Organization (WHO) classification
+Subjects must have had histologic verification of malignancy at original diagnosis or relapse; all subjects with relapsed or refractory solid tumors are eligible including primary or metastatic CNS tumors; in the case of diffuse intrinsic pontine glioma (DIPG), or optic pathway glioma, imaging findings consistent with these tumors will suffice without the need for biopsy for histologic verification
+Histologic confirmation of thymic carcinoma (World Health Organization [WHO] classification)
+Recurrent high grade glioma
+Histologic confirmation is not required for this if the patient has neurofibromatosis type 1 (NF-1) with magnetic resonance imaging (MRI) findings consistent with optic pathway glioma or juvenile pilocytic astrocytoma (JPA); any other tumors will need histological confirmation, either at the time of diagnosis or at the time of recurrence; the histological diagnosis includes World Health Organization (WHO) grade I JPA
+Patient with diagnosis of diffuse intrinsic pontine glioma
+Patients must have a recurrent supratentorial WHO grade III or IV malignant glioma based on imaging studies
+Prior histopathology consistent with a supratentorial WHO grade III or IV malignant glioma
+World Health Organization (WHO) performance status 0-2
+Diagnosis of AML (World Health Organization [WHO] classification definition of >= to 20% blasts)
+Prior bevacizumab for treatment of glioblastoma or high grade glioma
+Histologically confirmed diagnosis of a myelodysplastic syndrome, meeting criteria for any subtype in the French-American-British (FAB) or World Health Organization (WHO) classification systems with any International Prognostic Scoring System (IPSS) score
+Participant has a prior histologically-confirmed diagnosis of a grade III or IV glioma, or has a prior histologically-confirmed diagnosis of a grade II glioma and now has radiographic progression consistent with a grade III or IV malignant glioma (MG) after completing standard therapy
+Clinical and/or radiographic, progressive and resectable grade II glioma
+Histologically-confirmed diagnosis of a grade III or IV glioma (including glioblastoma, anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma), or has a prior, histologically-confirmed, diagnosis of a grade II glioma and now has radiographic findings consistent with a high-grade glioma (grade III or IV)
+High-grade glioma has recurred or progressed after prior treatment with brain radiation and temozolomide
+Patients must have a previously histologically or cytologically confirmed high grade glioma (astrocytic or oligodendroglial supratentorial tumors grade 3 or 4) that has been previously treated with fractionated radiation therapy and now shows evidence of recurrence
+Diagnosis of myelodysplastic syndrome (MDS) confirmed within 10 weeks prior to study entry according to World Health Organization (WHO) criteria; patients are either not eligible for or choose not to proceed with a stem cell transplant
+Histologically confirmed glioblastoma multiforme, World Health Organization (WHO) grade IV astrocytoma
+Patients must have histologically proven supratentorial low-grade glioma at initial diagnosis; pathology must have been reviewed by University of California at San Francisco (UCSF) neuropathology; eligible low-grade gliomas include: astrocytoma, oligodendroglioma and mixed oligoastrocytoma; pilocytic astrocytomas are excluded
+Patients with radiographically proven recurrent, intracranial high grade glioma will be eligible for this protocol; patients must have evidence of tumor progression as determined by RANO criteria following standard therapy\r\n* High grade glioma includes glioblastoma multiforme (GBM), gliosarcoma (GS), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), or malignant astrocytoma NOS (not otherwise specified)\r\n* Magnetic resonance imaging (MRI) must be performed within 21 days prior to enrollment, and patients who are receiving steroids must be on a stable or decreasing dose for at least 5 days prior to imaging; if the steroid dose is increased between the date of imaging and enrollment, a new baseline MRI is required\r\n* Patients must have completed only 1 prior course of radiation therapy and must have experienced an interval of greater than 12 weeks from the completion of radiation therapy to study entry
+Patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of a high grade glioma is made
+Patients with recurrent or progressive glioblastoma or other grade IV malignant glioma (e.g. glioblastoma, gliosarcoma, giant cell glioblastoma, etc.) who have failed prior radiation but who have not progressed/recurred on bevacizumab; patients will be eligible if the original histology was lower-grade glioma and subsequent diagnosis of glioblastoma or gliosarcoma is made
+Histologic diagnosis of glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV)
+Diagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteria
+Histologically proven diagnosis of glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV)
+Pathologically confirmed high-grade glioma (World Health Organization [WHO] grade 3 or 4), with documented computed tomography (CT) or magnetic resonance imaging (MRI) progression or recurrence; biopsy is also an acceptable method of confirming progression; if initial tumor was grade 2 glioma, histological confirmation of high-grade recurrence is required\r\n* After first interim analysis, if the study proceeds to enrollment of selected patients (only those who have PDGFR alpha-positive tumors), patients will be pre-registered for PDGFR alpha analysis and registered to the combination treatment schema only if PDGFR alpha-positive and all other enrollment criteria are met
+Newly diagnosed supratentorial brain lesion compatible with a high grade glioma (WHO III or IV) by magnetic resonance (MR) with no prior treatment with either gene therapy, chemotherapy or radiation treatments that is amenable to attempted gross total resection (GTR); “high grade glioma” can include: glioblastoma multiforme (WHO grade IV); anaplastic astrocytoma (WHO grade III); anaplastic oligodendroglioma (WHO grade III); and anaplastic ependymoma (WHO grade III)
+Intraoperative histological frozen section at the time of tumor resection compatible with high-grade glioma; if intraoperative diagnosis is not compatible with high grade glioma, the patient will not be treated
+Infratentorial high grade glioma
+Patients will have histologically proven intracranial glioblastoma multiforme (GBM) or gliosarcoma (GS); this includes treatment-naive patients with prior tissue diagnoses of lower grade gliomas that have been upgraded to GBM after repeat resection
+Patients must have recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma
+Histologically confirmed mantle cell lymphoma classified according to World Health Organization (WHO) criteria confirmed at MSKCC
+Patients with histologically proven recurrent intracranial malignant glioma will be eligible for the phase I/II component of this protocol; malignant glioma includes glioblastoma (GBM), gliosarcoma (GS), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), or malignant astrocytoma NOS (not otherwise specified); patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of a malignant glioma is made
+Patients must have a histologically confirmed diagnosis of supratentorial high-grade glioma or supratentorial ependymoma that is recurrent, progressive or refractory
+Participants will not be eligible if the original diagnosis was a lower grade glioma and a subsequent histologic diagnosis revealed glioblastoma
+Participants must have either:\r\n* Histologically confirmed low-grade gliomas as defined by, World Health Organization (WHO) classification I-II/IV; these tumors can include astrocytomas, oligodendrogliomas, and mixed variants such as oligoastrocytomas; WHO classification is not required when pathology can only confirm that glioma is low grade; Karnofsky performance status (KPS) must be >= 70 OR\r\n* Histologically confirmed favorable anaplastic glioma as defined by WHO grade III with either or both isocitrate dehydrogenase 1 (IDH1) mutation or 1p/19q codeletion; in addition, these participants must have a KPS >= 70
+World Health Organization (WHO) performance status =< 2
+Myelodysplastic syndrome as defined by World Health Organization (WHO) criteria
+Histologically confirmed diagnosis of World Health Organization (WHO) I-III meningiomas and hemangiopericytomas
+Subjects with pathologic evidence of an anaplastic oligodendroglioma or mixed glioma (i.e. oligoastrocytoma) are eligible; histopathologic diagnosis will be made using World Health Organization classification criteria; to qualify as a mixed tumor there must be a minimum of 25% oligodendroglial element
+Subjects with histologically confirmed high-grade glioma are eligible; diagnosis of high-grade glioma will be made on the basis of needle biopsy, open biopsy, or surgical resection
+Diagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms, PPV-MF or PET-MF per the IWG-MRT
+Histology other than astrocytoma grade IV
+Patients must have histologically proven GBM that is progressive or recurrent following standard RT and temozolomide (i.e., at least “biopsy-proven” recurrent disease); previous salvage therapies after first recurrence do not exclude subjects from this trial (e.g., anti-angiogenesis therapies, second- and third-line chemotherapies); patients will be eligible if the original histology was lower-grade glioma and a subsequent diagnosis of GBM is made; for subjects who have tumor resection within the translation sub-study, the pathology results will be reviewed post-surgery and prior to treatment on the main study
+Patients with histologically confirmed GBM and/or other glioma subtypes at the time of diagnosis or prior relapse.
+Confirmed histopathology of WHO grade III glioma or WHO grade IV GBM at primary diagnosis
+Histologically proven intracranial Glioblastoma Multiforme (GBM) with diagnosis established by biopsy or resection within 5 weeks prior to enrollment.
+Patients must have eligibility confirmed by rapid central pathology and central molecular screening reviews performed on APEC14B1:\r\n* Newly-diagnosed high-grade glioma such as anaplastic astrocytoma or glioblastoma\r\n* Negative results for H3 K27M by immunohistochemistry (IHC)\r\n* Negative results for BRAFV600E mutation by next-generation sequencing (NGS)
+Newly diagnosed glioblastoma (GBM) histologically proven, World Health Organization (WHO) grade IV GBM or WHO grade IV gliosarcoma.
+Confirmed diagnosis of de novo AML according to World Health Organization (WHO) 2016 classification
+Confirmed diagnosis of AML according to World Health Organization (WHO) 2016 classification
+Newly diagnosed, histologically-confirmed supratentorial World Health Organization (WHO) grade IV gliomas including glioblastoma (all variants) and gliosarcoma.
+Recurrent glioma, or tumor involving the brainstem or cerebellum. Prior low-grade glioma without prior RT, now with malignant progression are eligible.
+Have histologically confirmed World Health Organization grade IV glioma (glioblastoma [GB] or gliosarcoma).
+Newly diagnosed histologically confirmed unmethylated glioblastoma multiforme (World Health Organization [WHO] grade IV). Patients with secondary glioblastoma, in particular those who are IDH1 or IDH2 mutant, will not be excluded. Unmethylated MGMT must be confirmed by a polymerase chain reaction (PCR)-based assay.
+First or second recurrence of previously histologically confirmed glioblastoma (grade 4 astrocytoma)\r\n* NOTE: gliosarcomas and other grade 4 astrocytoma variants (e.g., giant cell) may be included, primitive neuroectodermal tumor (PNET) variants are excluded; grade 4 oligodendrogliomas or oligoastrocytomas are specifically excluded
+Histologically proven, newly diagnosed World Health Organization (WHO) grade III or IV astrocytoma that has a methylated MGMT promoter as assessed by the standardized institutional analysis
+Patients are eligible if they had a prior low grade astrocytoma that was not previously treated, and there is subsequent histological evidence of a diagnosis of grade III or IV astrocytoma
+Histologically-confirmed intracranial glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV) with evidence of clinical and radiographic (computed tomography [CT] or MRI brain) tumor progression (need not be biopsy proven)
+Patients must have histologically confirmed progressive brain metastases from melanoma, or recurrent/progressive malignant glioma (glioblastoma, anaplastic glioma), for which standard curative or palliative measures do not exist or are no longer effective
+Inclusion Criteria:\n\n        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please\n        visit www.BMSStudyConnect.com\n\n          -  Children and adolescents diagnosed with either:\n\n          -  Diffuse Intrinsic Pontine Glioma (DIPG), in first-line, after completion of standard\n             radiotherapy\n\n          -  High Grade Glioma (HGG), recurrent or progressive\n\n          -  Medulloblastoma, recurrent or progressive\n\n          -  Ependymoma, recurrent or progressive\n\n          -  Other high-grade tumors of the central nervous system, recurrent or progressive\n\n          -  Lansky play score (LPS) for =< 16 years of age or Karnofsky performance scale (KPS)\n             for > 16 years of age assessed within two weeks of enrollment must be >= 60\n\n          -  A tumor sample must be available for submission to central laboratory [not required\n             for DIPG]\n\n        Exclusion Criteria:\n\n          -  Participants with active, known or suspected autoimmune disease\n\n          -  Participants unable to taper steroids due to ongoing mass effect\n\n          -  Participants with low-grade gliomas or tumors of unknown malignant potential\n\n          -  Prior treatment with any drug that targets T cell co-stimulation pathways (such as\n             checkpoint inhibitors)\n\n        Other protocol defined inclusion/exclusion criteria could apply
+Participants must undergo central pathology review to histologically confirm the diagnosis of glioblastoma or variants (1 unstained slide or 1 haematoxylin and eosin [H&E] slide must be submitted to and reviewed by a pathologist at the Dana Farber Cancer Institute [DFCI] Coordinating Center prior to enrollment of the participant for central pathology review); participants will not be eligible if the prior diagnosis was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants was made (e.g. secondary GBM)
+Cytologically or histologically confirmed diagnosis of MDS or CMML according to the 2008 World Health Organization (WHO) classification.
+A single glioblastoma or gliosarcoma tumor with histopathological confirmation for first or presenting second recurrence of glioblastoma or gliosarcoma at the time of consent
+Histologically proven advanced MPM of biphasic or sarcomatoid histology. Biphasic MPM is defined using the World Health Organization's international histological classification of tumors as containing an epithelial and a sarcomatoid component with each component comprising at least 10% of the tumor
+Diagnosis of AML per World Health Organization criteria
+The subject must have histological confirmation of GBM (World Health Organization [WHO] grade IV)
+Subject has morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) and fulfills one of the following:
+Phase I: patients must have recurrent or refractory solid tumors or acute leukemia (limited to AML or ALL) or have been intolerant of prior therapies, confirmed by the Laboratory of Pathology, National Cancer Institute (NCI), e.g., solid tumors including rhabdomyosarcoma, Ewing sarcoma, soft tissue sarcomas; these may include primary neoplasms of the central nervous system, such as high-grade (World Health Organization [WHO] grade III-IV) glioma; patients with diffuse intrinsic pontine glioma (DIPG) or optic pathway glioma are exempt from histologic verification; for DIPG typical magnetic resonance imaging (MRI) findings must be present which include hypo- or isointense on T1-weighted imaging, hyperintense on fluid attenuation inversion recovery (FLAIR) or T2-weighted imaging, epicenter in the pons in the face of a typical clinical presentation; optic pathway glioma are located in the optic pathway and are typically hypo- or iso-intense on T1 and hyperintense on T2-weighted images
+Histologically confirmed diagnosis of World Health Organization grade III or IV malignant glioma
+Has more than three recurrences of high grade glioma; previous recurrences of low grade glioma is not considered
+Morphologically confirmed new diagnosis of AML in accordance with World Health Organization (WHO) diagnostic criteria
+Pathologically confirmed World Health Organization (WHO) grade IV glioblastoma or variants (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma) with adequate tumor material for genomic sequencing; participants will be eligible if the original diagnosis was a lower grade glioma and a subsequent histologic diagnosis of glioblastoma or its variants was made, and they received no prior therapy other than surgery
+Diagnosis of MDS according to World Health Organization (WHO) criteria or French-American-British (FAB) classification that must be confirmed by bone marrow (BM) aspirate and/or biopsy within 6 weeks prior to Screening.
+Recurrent grade 3 or 4 glioma, including astrocytoma, oligodendroglioma or mixed glioma with histologic confirmation at initial diagnosis or recurrence
+Newly diagnosed and histologically confirmed supratentorial World Health Organization (WHO) Grade IV astrocytoma status-post maximally achievable resection
+Histopathologically proven diagnosis of glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV) following either a surgical resection or biopsy
+Patients must have histologically or cytologically confirmed AML according to the World Health Organization (WHO) criteria
+Patient has had a prior, histologically-confirmed, diagnosis of a grade III or IV glioma (including glioblastoma, anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma), or has a prior, histologically-confirmed, diagnosis of a grade II glioma and now has radiographic findings consistent with a high-grade glioma (grade III or IV)
+Patient's high-grade glioma has recurred or progressed after prior treatment with brain radiation and temozolomide
+Histologically confirmed follicular non-Hodgkin lymphoma, World Health Organization (WHO) classification grade 1, 2, or 3a (> 15 centroblasts per high-power field with centrocytes present)\r\n* Bone marrow biopsies as the sole means of diagnosis are not acceptable, but they may be submitted in conjunction with nodal biopsies\r\n* Fine-needle aspirates are not acceptable\r\n* Failure to submit pathology within 60 days of patient registration will be considered a major protocol violation
+Histological confirmation of a high-grade malignant glioma is required; histologic diagnoses include, but are not limited to, anaplastic astrocytoma and glioblastoma multiforme; patients with DIPG are exempt from histologic verification if they have typical MRI findings of DIPG (i.e. hypo- or isointense on T1-weighted imaging, hyperintense on fluid-attenuated inversion recovery [FLAIR] or T2-weighted imaging, epicenter in the pons, > 50% of pons involved) in the face of a typical clinical presentation
+Patients with newly diagnosed or recurrent glioma of World Health Organization (WHO) grade III or IV (anaplastic astrocytoma [AA], anaplastic astro-oligodendroglioma [AO], or glioblastoma [GBM]) will be eligible for this protocol
+After surgery, a pathological diagnosis of malignant glioma (WHO Grade III or IV) will need to be established
+Documented diagnosis of primary myelofibrosis according to World Health Organization (WHO) criteria or post polycythemia vera (PV) myelofibrosis or post essential thrombocythemia (ET) myelofibrosis as per IWG-MRT criteria
+A diagnosis of ET or PV shall be made in accordance with the World Health Organization (WHO) (2008) criteria (Swerdlow 2008)
+1d. Glioblastoma -Enrollment Completed Have histologically confirmed World Health Organization Grade IV malignant glioma (glioblastoma).
+Diagnosis of WHO Grade IV glioblastoma or WHO Grade III anaplastic gliomas
+Patient must have evaluable disease by RECIST v1.1 for patients without glioma or by RANO or RANO LGG criteria for patients with glioma
+Relapsed or refractory CD25-positive AML [per World Health Organization (WHO)].
+Relapsed or refractory CD25-positive ALL [per World Health Organization (WHO)].
+Confirmed histological diagnosis of recurrent GBM or gliosarcoma
+Histologically confirmed glioblastoma. A local pathology report constitutes adequate documentation of histology for study inclusion. Patients with an initial diagnosis of a lower-grade glioma are eligible if a subsequent biopsy was determined to be glioblastoma.
+Prior treatment with TMZ for low grade glioma or glioblastoma.
+Diagnosis of a hematologic malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).
+Diagnosis of B-cell iNHL, DLBCL, MCL, or CLL as documented by medical records and with histology based on criteria established by the World Health Organization
+Age ? 18 years at the time of signing the informed consent form. 8. Central confirmation of diagnosis of previously untreated primary or secondary Myelodysplastic syndromes (MDS) as per World Health Organization (WHO) classification. Results of central pathology review are required prior to receiving the first dose of IP.
+AMKL PATIENTS: Patients must have a confirmed diagnosis (by blood or bone marrow) of relapsed/refractory acute megakaryoblastic leukemia (AMKL), as defined by World Health Organization (WHO) criteria\r\n* NOTE: if diagnosis was performed an outside facility, a copy of the report is sufficient for registration purposes; however, local pathology review at one of the main sites should still be obtained
+Patient must have documented diagnosis of MDS lasting at least three months (MDS duration >= 3 months) according to World Health Organization (WHO) criteria or non-proliferative chronic myelomonocytic leukemia (CMML) (white blood cell [WBC] < 12,000/mcL)
+Male or female patients, ages 18 years or older with pathologically confirmed relapsed or refractory B-cell lineage NHL who have failed or are intolerant to established therapy, or for whom no other treatment options are available. Refractory or relapsed B-cell NHL (per World health Organization [WHO] Classification system)
+Myelodysplastic Syndrome (MDS) according to the World Health Organization (WHO) 2008 classification
+Histologic documentation: newly diagnosed World Health Organization (WHO) grade IV intracranial glioblastoma or gliosarcoma; GBM with oligodendroglial features are NOT PERMITTED in this study if they are 1p19q codeleted; sites submitting GBM with oligodendroglial features will be asked to provide results of 1p/19q codeletion status
+Confirmation by central pathology review of WHO grade IV glioblastoma or gliosarcoma
+Histologically or cytologically confirmed recurrent or metastatic SCCHN\r\n* All primary sites are eligible excluding World Health Organization (WHO) type III or Epstein–Barr virus (EBV) nasopharyngeal (WHO type I and WHO type II allowed as long as they are EBV negative)
+World Health Organization (WHO) risk score 0-6
+For glioblastoma multiforme (GBM-2) cohort:
+Patients with brainstem tumors that do not meet these criteria or not considered to be typical intrinsic pontine gliomas will only be eligible if the tumors are biopsied and proven to have + RB and be the following according to the 2016 World Health Organization classification of tumors of the central nervous system: an anaplastic astrocytoma (IDH mutant, IDH wildtype, or NOS), glioblastoma (IDH mutant, IDH wildtype or NOS), diffuse midline glioma, H3 K27M mutant or H3 K27M negative, diffuse astrocytoma (IDH mutant, IDH wildtype or NOS).
+High-grade Glioma (HGG)
+Patients must have had histologically verified the following according to the 2016 World Health Organization classification of tumors of the central nervous system: anaplastic astrocytoma (IDH mutant, IDH wildtype, or NOS), glioblastoma multiforme (IDH mutant, IDH wildtype, or NOS), diffuse astrocytoma (IDH mutant, IDH wildtype or NOS)
+Newly diagnosed histologically confirmed glioblastoma multiforme (World Health Organization [WHO] grade IV); patients with secondary glioblastoma, in particular those who are IDH1 or IDH2 mutant, will not be excluded
+A diagnosis of SM per 2008 World Health Organization (WHO) criteria; patients with ASM and MCL, or SM-AHNMD are required to have at least one of the eligible organ damage findings as defined by the international consensus response criteria (Gotlib, 2013)
+Histologically confirmed diagnosis of World Health Organization (WHO) grade III (except anaplastic oligodendroglioma) or IV malignant glioma
+Has more than three recurrences of high grade glioma
+Histopathologically proven diagnosis of glioblastoma or gliosarcoma prior to registration by pathology report
+Subjects must have relapsed/refractory AML by world health organization (WHO) classification for which no standard therapies are available or anticipated to result in a durable remission. French- American- British system (FAB) subtype M3 will be excluded.
+A diagnosis of systemic mastocytosis (SM) per 2008 World Health Organization (WHO) Criteria
+Radiographically proven recurrent (>= first relapse), intracranial glioma
+Histologically documented diagnosis of proven glioblastoma (GBM)
+Patients must have histologic verifications of a glioblastoma multiforme, anaplastic astrocytoma, gliomatosis cerebri (World Health Organization [WHO] grade III or IV glioma with diffuse parenchymal and/or leptomeningeal involvement), or gliosarcoma at the time of study enrollment
+Patients with newly diagnosed intrinsic brainstem gliomas, defined as tumors with a pontine epicenter and diffuse rather than focal involvement of the pons, with or without extension to adjacent medulla or midbrain, are eligible without histologic confirmation; patients with brainstem tumors that do not meet these criteria or not considered to be typical intrinsic pontine gliomas will only be eligible if the tumors are biopsied and proven to be a grade III or IV glioma (anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma)
+Subject has a diagnosis of previously-untreated AML according to World Health Organization (WHO) classification [Swerdlow et al, 2008] as determined by pathology review at the treating institution.
+In Part 1, diagnosis of myelodysplastic syndrome (MDS) according to World Health Organization (WHO) criteria
+World Health Organization (WHO) performance status of 0, 1, or 2
+Performance status (World Health Organization [WHO] scale) < 2
+Histologically confirmed initial diagnosis of primary glioblastoma multiforme (GBM) or gliosarcoma (GS), now recurrent. Patients with recurrent/progressive disease whose initial diagnostic pathology confirmed GBM or GS will not need re-biopsy. Patients with prior low-grade glioma or anaplastic glioma are eligible, if histologic assessment demonstrates transformation to GBM or GS.
+Patients must have a histologically confirmed diagnosis of primary myelofibrosis (PMF), post-polycythemia vera (post-PV) myelofibrosis (MF), or post-essential thrombocythemia (post-ET) MF using World Health Organization Criteria
+Newly diagnosed and recurrent high grade gliomas (World Health Organization [WHO] grades III & IV) and high risk WHO grade II gliomas who are to begin treatment with monthly high dose temozolomide therapy
+Histologically confirmed newly diagnosed glioblastoma; patients with an initial diagnosis of a lower-grade glioma are eligible if a subsequent biopsy was determined to be glioblastoma and they received no prior treatment
+World Health Organization (WHO) performance score of 0 to 1 with life expectancy of at least 3 months
+Pathologically confirmed diagnosis of glioblastoma multiforme (GBM); or World Health Organization (WHO) grade IV (gliosarcoma)
+Histological confirmation of a high grade (grade 3 or 4) primary brain tumor either classified as a glioma (including astrocytoma, anaplastic oligodendroglioma and glioblastoma multiforme), medulloblastoma, atypical teratoid/rhabdoid tumor (AT/RT) or primitive neuroectodermal tumor (PNET)\r\n* Note: Patients with diffuse intrinsic pontine glioma (DIPG) are exempt from this confirmation of tumor if characteristic radiologic findings are noted on magnetic resonance imaging (MRI)
+Diagnosis of CLL meeting criteria established in the World Health Organization (WHO) classification of hematologic disorders
+JAK2V617F-positive PV or JAK2V617F-positive ET (confirmed by World Health Organization [WHO] diagnostic criteria)
+World Health Organization (WHO) Performance Status of 0 or 1
+Have histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma); participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made
+Patients must be at first or second relapse and clinically require reoperation for tumor progression within 4 to 6 weeks; Note: relapse is defined as progression following initial therapy (i.e., radiation, chemotherapy, or radiation + chemotherapy); if the participant had a surgical resection for relapsed disease and no anti-tumor therapy instituted for up to 12 weeks, this is considered one relapse; for participants who had prior therapy for a low grade glioma, the surgical diagnosis of a high grade glioma will be considered first relapse
+Have histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma); participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made
+Be at first or second relapse; Note: relapse is defined as progression following initial therapy (i.e., radiation +/- chemotherapy); if the participant had a surgical resection for relapsed disease and no antitumor therapy was instituted for up to 12 weeks, this is considered one relapse; for participants who had prior therapy for a low-grade glioma, the surgical diagnosis of a high-grade glioma will be considered the first relapse
+Subjects with primary CNS malignancy other than high grade glioma (Grade 3 or 4)
+Major Eligilbility Criteria\n\n          1. Signed written informed consent must be obtained and documented according to\n             International Conference on Harmonisation (ICH) and local regulatory requirements.\n\n          2. A histologically confirmed supratentorial glioblastoma (GBM) at first\n             recurrence/progression (except for transformation from previous low grade glioma)\n             following standard front-line therapy, for which treatment with temozolomide (TMZ)\n             would be acceptable as determined by the Investigator\n\n          3. Previously received standard front-line GBM treatment including maximal surgical\n             resection followed by external beam radiation therapy.\n\n          4. Patients may or may not be candidates for repeat surgical resection of the\n             recurrent/progressed GBM.\n\n          5. Patients must have unequivocal evidence of tumor recurrence/progression by MRI at a\n             minimum of 12 weeks following completion of chemoradiation or radiation therapy.\n\n          6. Patients must have measurable or non-measurable disease by response assessment in\n             neuro-oncology (RANO) criteria\n\n          7. ?18 years of age.\n\n          8. Eastern Oncology Cooperative Group (ECOG) performance status of 0 or 1
+World Health Organization Performance Status of 0 to 1 with no clinically significant deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks
+Histologically confirmed diagnosis of supratentorial WHO grade III or IV glioma (high grade glioma) that has undergone surgical biopsy or resection followed by adjuvant chemoradiotherapy, that has evidence of recurrence or progression based on imaging studies and a stereotactic biopsy is indicated for confirmation of recurrence/progression
+Patients must have measurable non-visceral lesion(s) that are evaluable by the modified World Health Organization (mWHO) criteria and immune-related response criteria (irRC).
+Histopathologically proven diagnosis of glioblastoma (GBM) or gliosarcoma or anaplastic astrocytoma (AA)
+Patients must have a histologically confirmed intracranial glioblastoma (GBM) (including any sub variants including but not limited to gliosarcoma [GS], glioblastoma with oligodendroglial features [GBM-O], and glioblastoma with primitive neuroectodermal tumor [PNET] features [GBM-PNET]); anaplastic astrocytoma (AA); anaplastic oligodendroglioma (AO); anaplastic oligo-astrocytoma (AOA) also called anaplastic mixed gliomas; malignant glioma NOS (not otherwise specified); patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of a high grade (malignant) glioma is made
+Patients with thymic carcinoma (formerly World Health Organization [WHO] type C)
+Glioblastoma or gliosarcoma in first or second recurrence only
+Multiple intracranial malignant glioma lesions
+Patients must have pathologically proven diagnosis of high grade glioma
+Patients must have histologically or cytologically confirmed mantle cell lymphoma as defined by the World Health Organization; all patients must have either t(11;14) by karyotype or fluorescent in-situ hybridization (FISH) or positive immunohistochemistry for cyclin D1
+World Health Organization (WHO) performance status 0-1
+World Health Organisation (WHO) Performance Status of 0 to 1.
+Evidence of an active optic glioma or other low-grade glioma, requiring treatment with chemotherapy or radiation therapy; subjects not requiring treatment are eligible for this protocol
+World Health Organisation (WHO) Performance Status of 0 or 1
+Subjects must have evaluable disease by RECIST v1.1 for subjects without glioma or by RANO criteria for subjects with glioma.
+Dose Expansion: Non-enhancing Glioma
+Subjects with histologically confirmed Grade IV malignant glioma
+Patients must have tissue confirmation of high grade (World Health Organization [WHO] grade IV) glioma including but not limited to glioblastoma, gliosarcoma, glioblastoma with oligodendroglial features, glioblastoma with primitive neuroectodermal tumor (PNET) features
+Histologically confirmed GBM (grade 4 astrocytoma) NOTE: gliosarcomas and other grade 4 astrocytoma variants (e.g., giant cell) may be included, primitive neuroectodermal tumor (PNET) variants are excluded; grade 4 oligodendrogliomas or oligoastrocytomas are specifically excluded
+Phase 2: Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET), Rhabdomyosarcoma, High Grade Glioma (HGG) (all must have measurable disease); exclusion of Diffuse Intrinsic Pontine Glioma
+Patients with histologically proven intracranial glioblastoma multiforme (GBM) or gliosarcoma (GS); patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of a GBM or GS is made; patients must have evidence of progression of the GBM or GS on magnetic resonance imaging (MRI) or computed tomography (CT) scan
+Diagnosis of histologically confirmed GBM (World Health Organization [WHO] grade IV)
+Subjects with a histologically confirmed diagnosis of MDS by FAB criteria, including both MDS and RAEB-T (AML with 20-30% blasts and multilineage dysplasia) by World Health Organization (WHO) classification are eligible.
+Histologically proven recurrent World Health Organization (WHO) grade II (atypical) or grade III (anaplastic) intracranial supratentorial meningioma; Memorial Sloan-Kettering Cancer Center (MSKCC) central review of histology is not required
+Histological diagnosis of: glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV) adapted recursive partitioning analysis (RPA) class III, IV, or V
+Histologically confirmed glioblastoma multiforme (GBM); rare GBM variants, secondary GBM, and suspected GBM are allowed
+Age >= 70, or age >= 60 ineligible for treatment with standard induction chemotherapy (based on physician discretion or patient refusal), with a new diagnosis of AML based on World Health Organization classification
+Prior radiation or chemotherapy for glioblastoma or glioma.
+Confirmed diagnosis of CMML using the World Health Organization (WHO) classification
+Recurrent high grade glioma
+primary myelofibrosis (PMF) per the revised World Health Organization (WHO) criteria
+Patients must have histologically confirmed newly diagnosed high-grade glioma (World Health Organization [WHO] grade III or IV)
+For Cohort 1 and 2, participants must have documented pathological diagnosis of a WHO grade II astrocytoma or oligoastrocytoma
+Pathological diagnosis for the recurrent disease demonstrate transformation to higher grade (i.e. WHO grade III or IV) gliomas, even if the initial diagnosis was WHO grade II glioma
+Histologically or radiologically confirmed diagnosis of brain cancer:\r\n* Glioblastoma (GBM), \r\n* Anaplastic astrocytoma (AA), \r\n* Anaplastic oligodendroglioma (AO), \r\n* Anaplastic mixed oligoastrocytoma (AMO), \r\n* Low grade gliomas, \r\n* Brain metastases, \r\n* Meningiomas, or\r\n* Leptomeningeal metastases
+Patients with histologically confirmed grade III or IV astrocytoma, oligoastrocytoma, and oligodendroglioma who are at first or second recurrence
+Diagnosis of HGG or DIPG; if histologic confirmation was obtained, diagnosis must be one of the following: anaplastic astrocytoma (World Health Organization [WHO] grade 3), anaplastic oligodendroglioma (WHO grade 3), anaplastic oligoastrocytoma (WHO grade 3), anaplastic ganglioglioma (WHO grade 3), pleomorphic xanthoastrocytoma with anaplastic features (WHO grade 3), malignant glioneuronal tumor, glioblastoma, or gliosarcoma (WHO grade 4)
+Patients must have a World Health Organization performance status =< 2
+Patients with World Health Organization performance status of 3 or 4
+Patients must have a recurrent supratentorial WHO grade IV malignant glioma based on imaging studies with measurable disease (>= 1 cm and =< 5.5 cm of contrast-enhancing tumor); prior histopathology consistent with a World Health Organization (WHO) grade IV malignant glioma confirmed by the study pathologist, Roger McLendon, or his designate
+Patients must have histologically confirmed diagnosis of glioblastoma multiforme (GBM) or anaplastic glioma, World Health Organization (WHO) grade 3 or 4
+Must have measurable disease by modified World Health Organization (WHO) criteria
+Diagnosis of myelodysplastic syndrome (MDS) confirmed within 10 weeks prior to study entry according to World Health Organization (WHO) or French-American-British (FAB) criteria; patients are either not eligible for or choose not to proceed with a stem cell transplant
+Patients with histologically confirmed supratentorial high-grade glioma will be eligible for this protocol.
+Patients with histologically proven supratentorial glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV astrocytoma) will be eligible for this protocol; patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or gliosarcoma is made prior to any definitive treatment (radiotherapy, chemotherapy)
+GBM patients only (enrollment plan 1)\r\n* Histologically confirmed glioblastoma multiforme World Health Organization (WHO) grade III-IV with recurrent or progressive disease after standard therapy\r\n* Age 16 years and older
+Patients must have EITHER histologically confirmed intracranial malignant glioma of the following types: glioblastoma, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic oligo-astrocytoma (AOA) also called anaplastic mixed gliomas, malignant glioma NOS (not otherwise specified); patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of a high grade (malignant) glioma is made; OR histologically confirmed low grade (World Health Organization [WHO] grade II) gliomas (such as low grade astrocytoma, low grade oligodendroglioma, low grade oligo-astrocytoma [mixed gliomas], or low grade glioma NOS) IF there is radiographic evidence by magnetic resonance imaging (MRI) of malignant transformation but histologic confirmation of high grade (malignant) transformation would not be otherwise undertaken for routine clinical care; inclusion of patients in this group will allow increased accrual rapidity by enrolling patients who are otherwise ineligible for almost all malignant glioma trials yet whom are treated presumptively for malignant glioma; the primary aim of the phase I study is not determination of efficacy; therefore, inclusion of such patients will not affect efficacy analyses (Participating site confirmation is adequate; MSKCC central review is not required)
+Multicentric glioma
+Patients must have a histologic diagnosis of glioblastoma (GBM), gliosarcoma, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), or anaplastic mixed oligoastrocytoma (AOA); patients are eligible if the original histology was lower-grade glioma
+Patients will have histologically proven intracranial glioblastoma multiforme (GBM) or gliosarcoma (GS); this includes treatment-naive patients with prior tissue diagnosis of lower grade gliomas that have been upgraded after repeat resection
+Diagnosis of essential thrombocythemia according to revised World Health Organization (WHO) 2016 criteria.
+Histologically confirmed diagnosis of a recurrent primary World Health Organization (WHO) grade IV malignant glioma (glioblastoma); patients with recurrent disease whose diagnostic pathology confirmed glioblastoma will not need re-biopsy; patients with prior low-grade glioma or anaplastic glioma (anaplastic astrocytoma or anaplastic oligodendroglioma) are eligible if histologic assessment demonstrates transformation to GBM
+Pathological diagnosis of astrocytoma grade 2, oligodendroglioma grade 2, or oligoastrocytoma grade 2 (mixed glioma containing astrocytoma and oligodendroglioma); pilocytic astrocytoma, ganglioglioma, pleomorphic xanthoastrocytoma, or dysembryoplastic neuroepithelial tumors are not eligible\r\n* NOTE: if the pathology from multiple procedures supports the diagnosis of a brain tumor, the qualifying pathology of grade 2 astrocytoma, oligodendroglioma, or oligoastrocytoma must be the most recent pathological diagnosis, and a pathological diagnosis of a grade 3 or grade 4 glioma must not have been made at any time
+Patients with glioblastoma multiforme or gliosarcoma
+Patients must have malignant glioma or recurrent ependymoma
+Histologically confirmed diagnosis of 1 of the following:\r\n* Anaplastic oligodendroglioma\r\n* Anaplastic oligoastrocytoma\r\n* Anaplastic astrocytoma
+World Health Organization (WHO) performance status 0-2
+The patient must have a histopathologic diagnosis of a World Health Organization (WHO) grade IV GBM as confirmed by the study pathologist, Roger McLendon, or his designate; the patient must undergo leukapheresis after definitive resection; residual radiographic contrast enhancement on post-resection computed tomography (CT) or magnetic resonance imaging (MRI) must not exceed 1 cm in diameter in two perpendicular axial planes; patients with evidence of contrast-enhancement exceeding 1 cm in diameter in two perpendicular axial planes after radiation will not be a candidate for the vaccine despite being previously enrolled and will be removed from the study and replaced; those that have transformed to a grade IV GBM from a lower grade glioma will be eligible so long as they are treatment naïve other than steroids, radiation therapy (RT), or TMZ
+Newly diagnosed tumor of the CNS, to include patients with:\r\n* Medulloblastoma (all histologic subtypes)\r\n* Supratentorial primitive neuro-ectodermal tumors (PNET) (including CNS neuroblastoma or ganglioneuroblastoma, medulloepithelioma, and ependymoblastoma)\r\n* Pineoblastoma\r\n* Atypical teratoid rhabdoid tumor (ATRT)\r\n* Choroid plexus carcinoma \r\n* High-grade glioma, including anaplastic astrocytoma (World Health Organization [WHO] grade III), anaplastic oligodendroglioma (WHO grade III), anaplastic oligoastrocytoma (WHO grade III), anaplastic ganglioglioma (WHO grade III), pleomorphic xanthoastrocytoma with anaplastic features (WHO grade III), high-grade astroblastoma, anaplastic pilocytic astrocytoma (WHO grade III), malignant glioneuronal tumor, glioblastoma multiforme (WHO grade IV) or gliosarcoma (WHO grade IV)\r\n* Patients with ependymoma (including all ependymoma histological variants)
+Histologic diagnosis of high-grade glioma, including anaplastic astrocytoma (WHO grade III), anaplastic oligodendroglioma (WHO grade III), anaplastic oligoastrocytoma (WHO grade III), anaplastic ganglioglioma (WHO grade III), pleomorphic xanthoastrocytoma with anaplastic features (WHO grade III), high grade astroblastoma (WHO grade III), anaplastic pilocytic astrocytoma (WHO grade III), malignant glioneuronal tumor, glioblastoma multiforme (WHO grade IV) or gliosarcoma (WHO grade IV)
+Patients with histologically proven supratentorial WHO grade IV glioma (glioblastoma or gliosarcoma) will be eligible for the study.
+Evidence of an optic glioma requiring treatment
+Subjects with cytologically/histologically confirmed MDS according to the World Health Organization (WHO) 2008 classification.
+Patients must have a previous morphologically confirmed diagnosis of AML based on World Health Organization (WHO) criteria
+Histologically proven supratentorial GBM or gliosarcoma
+Diagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteria
+MDS by World Health Organization (WHO) or French-American-British (FAB) classification
+Patients must have a histologically-confirmed primary diagnosis of high-grade glioma (HGG) (such as glioblastoma multiforme, gliosarcoma, anaplastic oligodendroglioma, anaplastic ganglioglioma, high grade astrocytoma, not otherwise specified [NOS]) that is recurrent or refractory to conventional therapy; patients with metastatic disease are not eligible; if there is evidence of the tumor arising from the ventricular system, patient is NOT eligible
+Histological diagnosis of GBM (WHO grade IV)
+World Health Organization (WHO) Performance Status (PS) ? 2
+Histology other than astrocytoma grade IV (GBM or gliosarcoma)
+RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients with progressive DIPG, as defined by progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (e.g., anticonvulsant or corticosteroid toxicity wean, electrolyte disturbances, sepsis, hyperglycemia, etc.), OR an increase in the bi-dimensional measurement, taking as a reference the smallest disease measurement recorded since diagnosis, OR the appearance of a new tumor lesion since diagnosis\r\n* Please note: patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation\r\n* Patients with pontine lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of malignant glioma World Health Organization (WHO) II-IV
+NON-PROGRESSED DIPG (STRATUM 2): Patients with DIPG who have not yet progressed by clinical or radiographic criteria\r\n* Please note: patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation\r\n* Patients with pontine lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of malignant glioma World Health Organization (WHO) II-IV
+Patients must have histologically confirmed supratentorial high grade glioma (grade III or IV glioma) that is progressive or recurrent following radiation therapy and chemotherapy; patients with grade IV glioma must have progressed or recurred after initial treatment with radiation and temozolomide; patients with grade III glioma must have received at least radiation and one regimen of chemotherapy (temozolomide or procarbazine, lomustine, vincristine [PCV] regimen)
+Confirmed diagnosis of AML, including treatment-related secondary AML (except prior MDS) according to World Health Organization (WHO) 2008 classification at treating institution
+Frozen section diagnosis of World Health Organization (WHO) grade IV glioma, confirmed with permanent section and immunopositive for IGF-1R
+Measurable disease by RECIST v1.1 for subjects with solid tumors without glioma, by modified RANO criteria for subjects with glioma, or by the revised IWG criteria for subjects with AITL
+Participants with glioblastoma are eligible for this study; these will include\r\n* Those with a histologically proven diagnosis of glioblastoma who have developed new changes on MRI following primary treatment\r\n* Those who received primary treatment for a histologically proven lower grade (2 or 3) glioma and who now progress with radiographic characteristics of transformed glioma
+Histologically confirmed GBM or World Health Organization (WHO) Grade IV variants (gliosarcoma, glioblastoma with oligodendroglial features, or giant cell glioblastoma).
+Histologically or cytologically confirmed unresectable GBM. Subjects with recurrent disease whose prior pathology demonstrated GBM will not need to be re-biopsied. Subjects with prior low-grade glioma or anaplastic glioma are eligible if histological assessment demonstrates transformation into GBM.
+Subject is defined as morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) and fulfills one of the following:
+Histologically confirmed glioblastoma multiforme (GBM) (World Health Organization [WHO] grade IV); rare GBM variants (e.g. gliosarcoma, giant cell GBM, small cell GBM, GBM with oligodendroglioma features, GBM with primitive neuroectodermal tumor [PNET] features) are allowed; patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of GBM is made
+Biopsy-proven diagnosis of cHL (regardless of Hodgkin/Reed-Stemberg [HRS] cell cluster of differentiation [CD]20 expression) per the World Health Organization classification criteria; lymphocyte predominant histology is excluded
+Confirmed MDS by bone marrow biopsy according to World Health Organization (WHO) or French-American-British (FAB) criteria
+Glioblastoma Multiforme (GBM)
+Histological confirmation of grade 3 or 4 glioma, including astrocytoma, oligodendroglioma, and mixed gliomas, as determined by pre-registration central pathology review (Phase I)
+Histological confirmation of glioblastoma multiforme (grade 4 astrocytoma) as determined by pre-registration central pathology review; note: gliosarcomas and other grade 4 astrocytoma variants (e.g., giant cell) are eligible; glioblastoma (GBM) with oligodendroglial features are NOT PERMITTED in this study if they are 1p19q co-deleted; sites submitting GBM with oligodendroglial features will be asked to provide results of 1p/19q co-deletion status (Phase II)
+The patient has a diagnosis of AML according to World Health Organization (WHO) criteria.
+Histologically proven intracranial glioblastoma multiforme (WHO grade IV glioma) or gliosarcoma. In addition, the Phase 1b cohort will include patients with progressive WHO grade III glioma.
+Patients will be eligible if the original histology was lower grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made.
+Must have histologically proven glioblastoma
+Evidence of an optic glioma, malignant glioma, malignant peripheral nerve sheath tumor, or other cancer requiring treatment with chemotherapy or radiation therapy
+Histologically or cytologically confirmed well differentiated low or intermediate grade (World Health Organization [WHO] Grade 1 or 2) NET of pancreatic, gastrointestinal, lung, or undetermined origin that is locally advanced or metastatic and has progressed within the past 12 months
+Have histologically or cytologically confirmed recurrent Grade 2 or 3 LGG (oligodendroglioma or astrocytoma according to World Health Organization 2016 classification).
+Diagnosis of histopathologically confirmed B-cell NHL (as per the World Health Organization [WHO] 2016 classification) including WM/LPL.
+Documentation that the participant has met the revised 2016 World Health Organization (WHO) criteria for the diagnosis of polycythemia vera (PV)
+Patients with newly diagnosed diffuse intrinsic pontine gliomas (DIPGs), defined as tumors with a pontine epicenter and diffuse intrinsic involvement of the pons, are eligible without histologic confirmation; patients with brainstem tumors that do not meet these criteria or not considered to be typical intrinsic pontine gliomas will only be eligible if the tumors are biopsied and proven to be an anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, anaplastic mixed glioma, or fibrillary astrocytoma\r\n* Patients with juvenile pilocytic astrocytoma, pilomyxoid astrocytoma, fibrillary astrocytoma, gangliogliomas, or other mixed gliomas without anaplasia are not eligible;\r\n* Patients with disseminated disease are not eligible, and magnetic resonance imaging (MRI) of spine must be performed if disseminated disease is suspected by the treating physician
+Histologically confirmed initial diagnosis of primary WHO Grade IV malignant glioma (glioblastoma), now recurrent; or Cohorts 2 and 3 only: progressive secondary brain tumor, has failed standard brain radiotherapy, and has brain tumor progression after at least one line of systemic therapy. Patients with progressive secondary brain tumors will not be enrolled under this protocol following the completion of Cohort 3.
+Patients must have histologically confirmed diagnosis of a recurrent/progressive World Health Organization (WHO) grade IV malignant gliomas (glioblastoma multiforme and gliosarcoma)
+Indolent NHL subtypes defined according to World Health Organization guidelines:
+Pre-study World Health Organization (WHO) performance status of 0, 1, or 2
+The patient has cytologically proven AML as defined by the World Health Organization (WHO) classification. The pretreatment AML karyotype should be documented.
+All patients must have had prior pathologic confirmation of tumor histology, anaplastic glioma (AG) or glioblastoma (GBM) and have supratentorial gliomas
+Patients must have histologically proven intracranial low-grade glioma at initial diagnosis; low-grade gliomas include: astrocytoma, oligodendroglioma and mixed oligoastrocytoma; pilocytic astrocytomas are excluded
+If most recent histology shows progression to high grade glioma, patients must have had prior radiotherapy in order to be eligible
+Inclusion criteria:\n\n        Phase I Part:\n\n          1. Histologically-confirmed WHO Grade III or IV malignant glioma that is recurrent after\n             prior chemoradiotherapy. Patients with prior low-grade glioma are eligible if\n             histologic assessment demonstrates transformation to WHO Grade III or IV malignant\n             glioma.\n\n          2. Age at least 18 years at entry\n\n          3. KPS at least 60%\n\n          4. Patients must have recovered from previous surgery and chemotherapy.\n\n          5. Written informed consent that is consistent with local law and ICH-GCP guidelines.\n\n        Phase II Part:\n\n          1. Histologically-confirmed WHO Grade IV malignant glioma at first episode of recurrence\n             after prior combined chemoradiotherapy. Patients with prior low-grade glioma are\n             eligible if histologic assessment demonstrates transformation to WHO Grade IV\n             malignant glioma and if prior treatment included temozolomide chemotherapy and\n             radiotherapy.\n\n          2. Bi-dimensionally measurable disease with a minimum measurement of 1 cm (10 mm) in one\n             diameter on Gd MRI performed within 14 days prior to first treatment (Day 1).\n\n          3. Age at least 18 years at entry\n\n          4. KPS at least 70%\n\n          5. Patients must have recovered from previous surgery and chemotherapy.\n\n          6. Written informed consent that is consistent with local law and ICH-GCP guidelines.\n\n          7. Patients receiving corticosteroids have to receive a stable or decreasing dose for at\n             least 14 days before start of study treatment.\n\n        Exclusion criteria:\n\n        Phase I and Phase II Parts:\n\n          1. Less than 12 weeks between radiotherapy and start of study treatment, unless new\n             enhancing lesion outside of radiation field or radiologically progressive on two\n             consecutive MRI scans at least four weeks apart or biopsy-proven recurrence.\n\n          2. Less than two weeks from surgical resection (one week from prior stereotactic biopsy)\n             or major surgical procedure.\n\n          3. Less than two weeks after previous chemotherapy (6 weeks from nitrosureas).\n\n          4. Treatment with other investigational drugs; participation in another clinical study\n             within the past 2 weeks before start of therapy or concomitantly with this study.\n\n          5. Progressive disease or toxicity =CTCAEv3 Grade 3 to protracted temozolomide dosing\n             (defined as temozolomide administered more than 5 days/28 day cycle).\n\n          6. Active infectious disease requiring intravenous therapy.\n\n          7. Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.\n\n          8. Gastrointestinal disorders that may interfere with the absorption of the study drug or\n             chronic diarrhea.\n\n          9. Serious illness or concomitant non-oncological disease considered by the investigator\n             to be incompatible with the protocol.\n\n         10. Patient is <3 years free of another primary malignancy except: if the other primary\n             malignancy is either not currently clinically significant or does not require active\n             intervention (such as a basal cell skin cancer or a cervical carcinoma in situ).\n             Existence of any other malignant disease is not allowed.\n\n         11. Cardiac left ventricular function with resting ejection fraction <50%.\n\n         12. Absolute neutrophil count (ANC) less than 1500/mm3.\n\n         13. Platelet count less than 100,000/mm3.\n\n         14. Bilirubin greater than 1.5 x upper limit of institutional norm.\n\n         15. Aspartate amino transferase (AST) greater than 3 x upper limit of institutional norm.\n\n         16. Serum creatinine greater than 1.5 x upper limit of institutional norm.\n\n         17. Patients who are sexually active and unwilling to use a medically acceptable method of\n             contraception.\n\n         18. Pregnancy or breast-feeding.\n\n         19. Patients unable to comply with the protocol.\n\n         20. Known pre-existing interstitial lung disease (ILD).\n\n        Phase I part only:\n\n        1. Less than four weeks from prior treatment with bevacizumab.\n\n        Phase II Part only:\n\n          1. Prior EGFR-directed therapy.\n\n          2. Prior bevacizumab therapy.\n\n          3. Patients presenting with second or higher number of episodes of recurrence.\n\n          4. Requirement of treatment with any of the prohibited concomitant medications listed in\n             Section 4.2.2 (Restrictions regarding concomitant treatment).
+Patients must have a histologically confirmed diagnosis of primary myelofibrosis (PMF), post-polycythemia vera (post-PV) myelofibrosis (MF), or post-essential thrombocythemia (post-ET) MF using World Health Organization Criteria
+Diagnosed with glioblastoma, gliosarcoma, small cell or large cell glioblastoma, glioblastoma with oligo features, glioblastoma with primitive neuroectodermal tumor-like components (GBM-PNET) features, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma who are clinically stable and have completed radiation therapy (excluding stereotactic radiosurgery) > 21 days and =< 24 months prior to enrollment; NOTE: clinical stability will be defined as a stable or improved Karnofsky performance status (KPS) compared to the prior month
+Undergone surgery (gross total or subtotal resection) or biopsy and will have been treated with concurrent radiation therapy and chemotherapy as standard of care for glioblastoma, gliosarcoma, small cell or large cell glioblastoma, glioblastoma with oligo features, glioblastoma with primitive neuroectodermal tumor-like components (GBM-PNET) features, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma patients; Note: radiation must be completed, but chemotherapy is allowed; patients who are currently using Optune device will be eligible to participate in this trial
+Patients with pontine glioma are not eligible
+Grade II and III gliomas IDH mutant gliomas including; diffuse astrocytoma, anaplastic astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, anaplastic oligoastrocytoma
+Histologic diagnosis of glioblastoma (WHO grade IV) or pilocytic astrocytoma (WHO grade I)
+Histologically proven diagnosis of supratentorial, World Health Organization (WHO) grade II or III astrocytoma, oligodendroglioma or oligoastrocytoma, with IDH mutation confirmed by central review
+Patient with diagnosis of glioma, or other World Health Organization (WHO) grade II - IV primary brain tumor
+Patients must have histologically confirmed World Health Organization (WHO) grade 2 or 3 gliomas
+COHORT B SPECIFIC INCLUSION: Patients with histologically confirmed glioma of any grade (II-IV) who are planned for a standard of care surgical debulking/resection and for whom participation in this study would not cause a medically unacceptable delay in surgery
+Must have histologically confirmed DLBCL, including de novo disease or transformed disease from indolent NHL. a. High-grade B-cell lymphoma (BCL) with MYC and BCL-2 and/or BCL-6 translocations (double-hit DLBCL under DLBCL, not otherwise specified [NOS], based on the 2008 World Health Organization [WHO] classification criteria) is not eligible for this study.
+For Part A, participants must have histologically confirmed solid tumors, CNS tumors, or lymphoma based upon biopsy or surgery at initial diagnosis and/or relapse/progression; the only exception to histologic confirmation is for pediatric tumors that are routinely diagnosed exclusively by standard clinical imaging criteria: diffuse intrinsic pontine glioma and optic pathway glioma
+Histologically proven diagnosis of glioblastoma or other grade IV malignant glioma (including variants of glioblastoma i.e., gliosarcoma, giant cell glioblastoma, etc.).
+PATIENT ONLY: Patients with a diagnosis of HGG or low grade glioma (LGG), based on radiographic or pathologic diagnosis of grade III or IV listed in the medical records, or patients with a malignancy that has metastasized to the brain
+Diagnosis of localized low grade glioma (e.g., pilocytic astrocytoma, optic pathway glioma, oligodendroglioma, ganglioglioma, pleomorphic xanthoastrocytoma [PXA]), craniopharyngioma, ependymoma, or germ cell tumor
+BRAIN CANCER: Histologically confirmed high grade glioma
+SUBJECT: A child with diffuse intrinsic pontine glioma (DIPG) or recurrent high grade brain tumors will be excluded.
+Patients must have histologically confirmed diagnosis of glioma (either low or high grade) and be either chemotherapy naive or non-naive and scheduled to receive temozolomide-based +/- bevacizumab-based chemotherapy; patients with recurrent disease whose diagnostic pathology confirmed glioma (either low or high grade) will not need re-biopsy
+Patients must have histologically confirmed high grade glioma by pathology (World Health Organization [WHO] grade III and IV)
+Patients with newly diagnosed World Health Organization (WHO) grade III or IV astrocytoma who will undergo concomitant radiation and temozolomide followed by adjuvant temozolomide
+Patients must have histologically confirmed high grade astrocytoma, WHO grade III or IV, by pathology
+Receiving health care primarily through an health maintenance organization (HMO)
+Patients must have had radiation therapy for a histologically confirmed CNS tumor including, but not restricted to glioma, astrocytoma, medulloblastoma or other embryonal tumors; patients with diffuse intrinsic pontine gliomas may be enrolled without pathologic confirmation
+Attained menopause as defined by World Health Organization Criteria
+Newly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm, based on the World Health Organization (WHO) 2008 classification (at Screening);
+Patients must have a World Health Organization performance status of =< 2
+Pediatric patients who will receive cranial radiotherapy for brain tumors; this could include but is not limited to: low grade glioma, high grade glioma (to include grade III but not grade IV glioma), germ cell tumors, primitive neuroectodermal tumors, craniopharyngioma, or medulloblastoma
+Diagnoses excluded include: glioblastoma multiforme, gliosarcoma, diffuse pontine glioma, or other tumors presumed to have expected median survival per the investigators of less than 1 year
+Patients with a suspected diagnosis of new, recurrent, or transformed glioma (WHO grade I-IV) scheduled for craniotomy at Duke University Medical Center (DUMC)
+Patients must have histologically-confirmed, newly-diagnosed malignant glioma (glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, or anaplastic oligodendroglioma) and are scheduled to receive radiotherapy (for a total of 54-60 Gy) and concomitant daily temozolomide therapy (at a dose of 75 mg/m^2 for one complete 6-week cycle)
+Histologically confirmed BE with high grade dysplasia, invasive carcinoma of the esophagus, low grade dysplasia
+Patients must have histologically proven glioblastoma or gliosarcoma which is progressive or recurrent following radiation therapy +/- chemotherapy
+Histologically confirmed supratentorial glioblastoma or other WHO grade III or IV malignant glioma from archival tissue.
+Score of >= 8 on the World Health Organization (WHO) Alcohol Use Disorders Identification Test (AUDIT, sensitivity of 0.8)
+Histologically proven intracranial glioblastoma or gliosarcoma at initial surgery\r\n* Patients will be eligible if the original histology was low-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made (high-grade transformation)
+Subjects must have a known or presumed radiological diagnosis of glioblastoma (GBM); for presumed diagnosis of GBM, histological confirmation of GBM must be completed within 12 weeks of enrollment; (subjects will be removed from study and non-evaluable if no histologic diagnosis of GBM is confirmed)
+Participants must have histologically confirmed glioblastoma and evidence of recurrence; patients with low-grade tumors who have progressed to glioblastoma are eligible
+Tumor pathology: suspected or confirmed newly diagnosed or recurrent malignant gliomas World Health Organization (WHO) grade IV
+Individuals without a probable or expected grade IV glioma
+Pathologically confirmed, well differentiated functioning or non-functioning metastatic GEP-NET (Grade I and II as per World Health Organisation classification 2010)
+Histological diagnosis of glioma or
+Patients with histologically proven high grade glioma
+Histologically-confirmed high-grade glioma
+Participants must have histologically confirmed glioblastoma and evidence of possible tumor progression on imaging; patients with low-grade tumors who have progressed to glioblastoma are eligible
+Preoperative diagnosis of either presumed first-time low or high grade glioma or recurrent glioma (astrocytoma, oligodendroglioma, mixed oligo-astrocytoma, anaplastic astrocytoma, and glioblastoma multiforme) or metastasis, or meningioma
+Histologically confirmed newly diagnosed grade IV malignant glioma; Note: grade III patients are no longer being enrolled
+Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis per World Health Organization 2008 criteria
+Primary diagnosis of a glioblastoma
+Suspected or histopathologically proven diagnosis of high or low grade glioma, or a tumor suspected to harbor an isocitrate dehydrogenase (IDH) mutation
+Patients must have a malignant brain tumor histologically confirmed as: glioblastoma multiforme, anaplastic astrocytoma, or anaplastic oligodendroglioma, either at initial diagnosis or at the time of tumor relapse (patients treated at relapse do not require re-confirmation of histopathology that was determined at initial diagnosis); or patients must have typical clinical and radiological (MRI) characteristics of a malignant glioma of the brain stem
+NF1-associated optic pathway glioma (OPG) will be defined as radiographic evidence of glioma along the optic nerve, chiasm, tract or radiation in a child with NF1
+Patient must have histological verification of one of the eligible diagnosis listed below; biopsy is required at time of diagnosis with the exception of optic pathway tumors and diffuse intrinsic pontine gliomas (DIPG); patients with spinal cord disease are eligible if they have a lesion > 1 cm in 2 dimensions; the following histologies are eligible:\r\n* Astrocytoma variants: fibrillary, protoplasmic, mixed\r\n* Pilocytic astrocytoma, including pilomyxoid variants\r\n* Pleomorphic xanthoastrocytoma\r\n* Infantile desmoplastic astrocytoma\r\n* Ganglioneuroma\r\n* Oligodendroglial tumor\r\n* Mixed glioma (including oligoastrocytoma)\r\n* Anaplastic astrocytoma\r\n* Anaplastic oligoastrocytoma\r\n* Anaplastic oligodendroglioma\r\n* Anaplastic ganglioglioma\r\n* Glioblastoma multiforme (including giant cell and gliosarcoma types)\r\n* Medulloblastoma\r\n* Ependymoma\r\n* Diffuse intrinsic pontine gliomas (DIPG)\r\n* Other rare malignant CNS tumors (i.e., pinealblastoma, small cell astrocytoma, etc.)
+Participants must have histologically or cytologically confirmed newly-diagnosed glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV/IV) and be planning to undergo standard chemoradiation treatment
+Patients must have histologically confirmed diagnosis of classical Hodgkin lymphoma including nodular sclerosis, mixed cellularity, lymphocytic-rich, and lymphocyte depleted subtypes by the 4th edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues published in 2008
+Pathologic evidence (either diagnostic pathology slides or pathology report) of a diagnosis of World Health Organization (WHO) grade II or III glioma prior to treatment with temozolomide or PCV chemotherapy
+Patients must have had prior central nervous system (CNS) radiotherapy for their glioma, including standard doses for low-grade or high-grade glioma as well as non-standard dose and fractionation, including hypofractionated regimens, stereotactic radiosurgery, etc
+Patients entering into this study will have the presumptive diagnosis of high grade or low grade glioma based on imaging studies, or will have recurrent high-grade or low grade gliomas that have previously undergone diagnosis (astrocytoma, oligodendroglioma, mixed oligoastrocytoma, anaplastic astrocytoma, and glioblastoma multiforme); both of these groups will be undergoing craniotomy for tumor resection
+Suspected new diagnosis or suspected recurrence of glioma
+Patients must have been diagnosed with high-grade glioma:\r\n* World Health Organization (WHO) grade III: anaplastic astrocytoma, oligodendroglioma, ependymoma, or oligoastrocytoma; OR\r\n* WHO grade IV: glioblastoma multiforme; or neuroepithelial tumors of uncertain origin (polar spongioblastoma, astroblastoma, or gliomatosis cerebri)
+Patients with low-grade (WHO grade I or II) glioma
+Subjects must have a clinically documented primary brain tumor for which resection is clinically indicated; individuals with suspected newly diagnosed or recurrent malignant gliomas will be considered eligible for the study; the anticipated histology at resection should include: anaplastic astrocytoma (10002224), anaplastic ependymoma, anaplastic oligodendroglioma, astrocytoma malignant not otherwise specified (NOS) (10003572), glioblastoma (10018336), glioblastoma multiforme (10018337), or gliosarcoma (10018340)
+Any patient with suspected new or recurrent high grade glioma on diagnostic MR imaging who will undergo a resection
+Patients must have clinically documented primary brain tumor for which resection is clinically indicated; radiographic findings should be consistent with high grade glioma
+Preoperative diagnosis of recurrent high-grade glioma having EGFR positive tissue from prior surgery
+Unstable health
+Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumor (according to World Health Organization [WHO 2000] classification).
+Diagnosis of BRAF V600 mutant High Grade glioma that has relapsed, progressed or failed to respond to frontline therapy
+Diagnosis of BRAF V600 mutant Low Grade glioma whose tumor is unresectable and who require treatment